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In this thesis the regulation of the oncogenic kinase Pim-1 and the microRNA cluster 
miR-17-92 has been investigated using the leukemia cell line K562 as a model system. 
Pim-1 and miR-17-92 have been reported to be highly expressed in the context of 
leukemia cells as well as in other cancer cell lines, albeit little is known about mechanisms 
leading to their overexpression. The aim of the work presented here was to evaluate the 
functions of Pim-1 in the promotion of tumorigenesis and to clarify its regulation, with the 
goal of exploring its potential for therapeutic interference. Several targets of the miR-17-
92 encoded miRs have been identified in different cellular contexts, and probably more 
will be found in the future. Nevertheless, many open questions concerning the regulation 
of the cluster still remain unanswered. For those reasons, we focussed our efforts on 
transcriptional regulation of the cluster in K562 cells, as well as on the cluster's impact on 
one of its targets, the cell cycle regulator p21. 
High expression levels of the Pim-1 kinase are characteristic for K562 cells. At the protein 
level, degradation of Pim-1 is promoted by the phosphatase PP2A. Inhibition of PP2A 
thus increases Pim-1 levels. Within the context of this work, it was shown by our group 
that inhibition of PP2A by ocadaic acid (OA) leads to a temporary increase of Pim-1 
followed by a complete downregulation. This was accompanied by an upregulation of p21 
which under normal growth conditions is not found at the protein level in this cell line. 
The cellular phenotype during OA-treatment changed from proliferation to apoptosis and 
siRNA-targeting of p21 delayed the onset of this apoptotic response, indicating that 
downregulation of p21 in K562 cells contributes to their anti-apoptotic and proliferative 
phenotype.  
Interestingly, p21 protein is not found at normal growth in K562 cells, although 
substantial amounts of its mRNA can be detected. This implicates a posttranscriptional 
silencing mechanism. Here we found that p21 is a target of miR-17-5p and miR-20a, both 
miRs being encoded in the miR-17-92 cluster. We could prove this in two ways. First, we 
cloned the p21 3'-UTR into a reporter vector. Mutation of the two predicted miR-binding 
sites in the respective constructs revealed regulation by those miRs as inferred from an 
increase of reporter activity. Second, we interfered with microRNA target-binding by 
application of antisense molecules directed against mature miR-17-5p and miR-20a. For 
this, we used locked nucleic acids (LNAs), as those modified oligonucleotides bind with 
largely increased affinity to their complementary strands. Current AntimiR approaches 
Summary 
 
 
mostly rely on the use of 2´-O-Methyl-RNA molecules for targeting of mature miRs, as 
this modification stabilizes the molecules against nucleases compared to unmodified 
RNA. AntimiRs are designed to be complementary over the whole length of the targeted 
miR (22-24 nt). Here it was established in a proof of principle experiment that LNAs of 
only 14 nucleotides could efficiently abolish miR-function in vivo. For this, luciferase 
reporter constructs containing a let-7a binding site were generated. In K562 cells let-7a is 
abundantly expressed, so constructs were silenced when transfected, but not so in co-
transfection experiments with respective LNAs targeting let-7a. LNA-AntimiRs, 8, 10, 12 
or 14 nucleotides in length, were tested, and even the 8-mer showed some let-7a-specific 
derepression effect. With this tool at hand, we targeted miR-17-5p and miR-20a to 
evaluate the effects on cellular p21 protein levels. In Western blot analysis we found an 
induction of p21 protein upon transfection with LNA 14-mers against miR-17-5p and 
miR-20a. By this experimental approach, we were able to demonstrate the importance of 
translational downregulation of the p21 protein in K562 cells that in combination with 
Pim-1 overexpression is supposed to contribute to the observed proliferative phenotype. 
In the same study, siRNA-targeting of Pim-1 revealed the dependency of K562 cells on 
this kinase to maintain proliferation. Pim-1 is thus an appealing target for therapeutic 
intervention. We asked if in addition to transcriptional regulation also posttranscriptional, 
i.e. translational regulation, may contribute to the high levels of Pim-1 protein in K562 
cells.  The browser tool TargetScanHuman (http://www.targetscan.org/) predicts several 
miR-binding sites in the Pim-1 3´-UTR. Among those with high confidence value was 
miR-33.  A profiling of miRs revealed that in K562 cells miR-33 is expressed at low 
levels compared to miR-17-5p or miR-20a, and other miRs such as miR-16-1 or miR-214. 
This suggested that cellular miR-33 downregulation may contribute to the observed Pim-1 
expression. To pinpoint this issue, construction of luciferase reporter vectors with Pim-1 
3´-UTRs and mutated miR-33 binding sites was performed in order to determine the role 
of miR-33 target-interaction on Pim-1 levels. Those experiments confirmed the prediction 
that Pim-1 is targeted by miR-33 as mutated constructs showed increased reporter 
expression. The application of miR-33 Mimics (artificially synthesized double-stranded 
RNA molecules recapitulating mature miRNA structures) reduced respective reporter 
levels. Furthermore, it was shown by our group that miR-33 Mimic transfection also 
efficiently downregulates Pim-1 at the protein level. Additionally, miR-33 Mimics 
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reduced proliferation of K562 cells. Finally, LNA-AnitimiRs against miR-33 slightly 
increased reporter expression, suggesting that basal miR-33a levels in K562 cells are 
responsible for minor repression effects. Overall, we could clearly identify Pim-1 as the 
first experimentally validated target of miR-33. 
Now that we had evaluated p21 as a target of the miR-17-92 cluster, we wanted to shed 
some light on the cluster regulation itself. The screening of several cancer cell lines 
confirmed the high expression of the cluster in K562 cells, as well as in lung cancer cell 
lines. We speculated on the coincidence of high miR-17-92 expression and Pim-1 
expression. The miR-17-92 cluster is transcribed as part of a large locus on chromosome 
13 (open reading frame 25), but also an internal promoter immediately in front of the 
cluster start site is predicted by an online promoter-browser (http://www.flybase.org). 
Furthermore a polyadenylation site at the end of the cluster was recently published, 
implicating that the cluster could be transcribed or regulated independently of the entire 
locus. We thus cloned segments 5´ the internal start site including the predicted promoter 
into a luciferase reporter vector to test the promoter activity of those segments. The tested 
segments were indeed shown to have promoter activity, and we were able to demonstrate 
that mutation of two non-consensus TATA-boxes located in the predicted promoter 
reduces activity of the respective construct. Furthermore, under Pim-1 knockdown 
conditions, expression of reporter constructs containing the internal promoter segments 
increased. Likewise, qRT-PCR experiments demonstrated increased miR-17-92 cluster 
expression under Pim-1 knockdown conditions.  It is known that, among other targets, 
Pim-1 phosphorylates Heterochromatin Protein 1γ (HP1γ) thus modulating its effects on 
chromatin modification. Possibly, this is a mechanism how   Pim-1 can regulate miR-17-
92 expression. To evaluate this, our group conducted chromatin immunoprecipitation 
(CHIP) experiments that show decreased binding of HP1γ to the miR-17-92 cluster region 
under Pim-1 knockdown. Under normal growth conditions, Pim-1 itself is also associated 
with the cluster region, except for the subregion harbouring the inernal promoter. At this 
time point, the exact mechanism of Pim-1 dependent miR-17-92 regulation remains 
elusive, but it is surprising that silencing of Pim-1 even increases cluster expression. 
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1 Introduction 
1.1 RNAi  
RNA interference is a regulatory interaction between several classes of RNA molecules 
mediated by protein components. In general, short dsRNAs (21-24 nts) are generated from 
longer precursor molecules by the action of the enzyme Dicer (Du and Zamore 2005).  
Those so-called short interfering RNAs (siRNAs) are transferred to a protein complex 
named RISC. In this complex one of the two RNA strands is removed and degraded while 
the remaining strand is able to pair with a complementary sequence on a messenger RNA. 
This interaction facilitates degradation of the targeted mRNA. So-called microRNAs 
(miRNAs) are undistinguishable from siRNAs in their mature form but the way they are 
generated differs. In most cases, miRNAs can exhibit several effects, e.g. degradation or 
storage of targeted mRNAs, or translational repression due to interference with 5´ cap 
recognition (Mathonnet, Fabian et al. 2007). Also, transcriptional activation has been 
shown very recently (Place, Li et al. 2008). MiRNAs bind specifically to complementary 
sites in 3´-UTRs of mRNAs and thus modulate translation. Several miRNAs can be 
encoded in the same genomic region, a situation in which one speaks of a miRNA cluster. 
A prominent miRNA cluster is the miR-17-92 cluster encoding 7 miRNAs (see below). 
RNAi has been regarded as an ancient defense mechanism against viral RNAs. Nowadays 
widespread regulation of transcriptome via RNAi is recognized as an intricate and 
extensive layer of cellular regulation. In animals, endogenously expressed microRNAs 
(miRNAs) are transcribed from introns (40%), exons (30%), or from intergenic regions 
(30%) by RNA polymerase II (Rodriguez, Griffiths-Jones et al. 2004). Those primary-
miRNAs (pri-miRNAs) can be in the size of up to several hundred nucleotides and are 
capped at the 5´end as well as poly-adenylated at their 3´end in most cases. After this step, 
they enter a so-called microprocessor complex where they are processed to pre-miRNAs 
of 60-70 nucleotides containing a 5´phosphate and a 3´overhang of two nucleotides. Pre-
miRNAs are exported from the nucleus to cytoplasm via exportin-5. The enzyme Dicer 
then cleaves the pre-miRNA to generate a mature miRNA that is transferred to the RNA-
induced silencing complex (RISC). Within the complex the antisense strand can target and 
pair with respective mRNAs (Kutter and Svoboda 2008) (see figure 1.1). The most 
essential region for pairing with the target site is from nucleotides 2-8 of the miRNA´s 
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5´end (Doench and Sharp 2004; Brennecke, Stark et al. 2005). Further determinants of 
target specificity are base-pairing between bases 13-16 of the miRNA and the target 
region, so that a bulge can form (nucleotides 9-11) between two paired regions. Proximity 
to other microRNA target sites and a high AU-content near the target site also contribute 
to efficient targeting. A minimal distance (15nt) to the stop codon is required, and it could 
be shown that 5´ and 3´ ends of the 3´-UTR are more apt for efficient miRNA-target 
recognition (Grimson, Farh et al. 2007). Several other criteria such as sequence 
conservation of target sites in 3´-UTRs are used by different miRNA target prediction 
tools (e.g. TargetScan)(Yoon and De Micheli 2006; Maragkakis, Reczko et al. 2009). In 
general, integration of both, experimental and computational methods will lead to more 
accurate target prediction (Chaudhuri and Chatterjee 2007; Oulas, Boutla et al. 2009). The 
binding of proteins to uridine rich regions near miRNA target sites can also influence its 
accessibility. This shown was shown for the RNA-binding protein Dnd1that binds to an 
uridine rich sequence and thus blocks translational repression by the microRNA-RISC 
complex  (Kedde, Strasser et al. 2007). 
Many cellular processes are now known to be regulated by miRNAs and their functions 
can be found especially in development and cell cycle regulation, as well as in apoptosis 
or metabolic processes (Lee, Risom et al. 2006; Carleton, Cleary et al. 2007; Aumiller and 
Forstemann 2008; Wang and Blelloch 2009). 
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Figure 1.1 miRNA pathways in animals. Taken from reference” Kutter and Svoboda 
2008”. For details see text and reference. 
 
1.2 miRNAs in cancer 
In cancer cells several layers of regulation and signaling may be involved in malignant 
transformation. Since discovery of miRNAs, many studies have shown the role of 
miRNAs in cell cycle regulation and apoptosis (Cimmino, Calin et al. 2005; Linsley, 
Schelter et al. 2007) as well as in transformation and expression of metastatic phenotypes 
(Asangani, Rasheed et al. 2008; Valastyan, Reinhardt et al. 2009). One of the most 
prominent proto-oncogenes, c-Myc, was shown to be regulated by the let-7a microRNA 
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(Sampson, Rong et al. 2007). With respect to therapeutic approaches, transcriptomics of 
small RNAs may shift emphasis from small molecule inhibitors to small RNA inhibitors. 
Good known examples are miR-15 and miR-16 that were shown to induce apoptosis by 
targeting the mRNA of the anti-apoptotic protein BCL2 (B cell lymphoma 2) (Cimmino, 
Calin et al. 2005). Calin et al have evaluated the role of miR-15a and miR-16 as tumor-
suppressor genes using in vivo models in mice (Calin, Cimmino et al. 2008). The same 
authors have shown the down-regulation of miR-15 and miR-16 in B cell chronic 
lymphocytic leukemia (B-CCL) samples from patients (Calin, Dumitru et al. 2002). In 
around 70 % of the samples the respective gene locus (13q14.3) was deleted or down-
regulated. Linsley et al. (2007) show rather intricate regulation of a whole network of cell 
cycle regulators that are targeted by the miR-16 family and support the current view of 
expression fine tuning by miRNAs as proposed by Bartel and Chen (Bartel and Chen 
2004). In this respect, the categorization of miRNAs into classical proto-oncogenes and 
tumor-suppressors may not be appropriate in many cases. Different or in some cases 
contradicting results may also arise from usage of different cell lines in those studies. At 
the same time, distinct expression patterns of miRNAs allow classification of cancer cell 
identities (Lu, Getz et al. 2005; Lee, Gusev et al. 2007; Gibcus, Tan et al. 2009). For 
example, miR-143 and miR-145 are downregulated in several B-cell malignancies (e.g. in 
chronic lymphocytic leukemia, CLL) (Akao, Nakagawa et al. 2007) and colon cancer 
(Cummins, He et al. 2006), as is miR-155 in some subtypes of Burkitt Lymphoma 
(Kluiver, Haralambieva et al. 2006). On the other hand, miR-155 is upregulated in distinct 
cases of pediatric Burkitt Lymphoma (Metzler, Wilda et al. 2004) obviating the 
difficulties in assigning phenotypes to the expression status of single microRNAs. To date 
emphasis is put on miRNA targets and their interaction with miRNAs, but for a better 
understanding of interactions between cellular regulatory layers (e.g. proteomics, 
transcriptomics, miROmics, metabolomics) and thus cell fate, the activation or 
transcriptional regulation of miRNAs itself needs detailed evaluation.  
 
1.3 miR-17-92 cluster 
MicroRNAs regulate a lot of cellular functions during normal cell cycle as well as in 
development and disease. It is thus interesting to find a cluster containing seven miRNAs 
(miR-17-3p/5p, miR18a, miR-20a, miR-19a, miR19b-1, and miR-92a-1) that seem to be 
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co-expressed and are involved in many cancer pathologies. Ota et al (Ota, Tagawa et al. 
2004) showed that the miR-17-92 polycistron located on chromosome 13 ORF 25 is 
amplified in B cell lymphomas. He et al (He, Thomson et al. 2005) further investigated 
the role of this cluster and found that it accelerates tumor growth in cooperation with c-
Myc in a mouse B cell lymphoma model. Interaction of the cluster with c-Myc was shown 
to modulate the expression of the transcription factor E2F1 (O'Donnell, Wentzel et al. 
2005). The authors could show binding of c-Myc at the cluster locus via chromatin 
immunoprecipitation assays (CHIPs). Venturini et al. (Venturini, Battmer et al. 2007) 
confirmed the connection between c-Myc and the cluster. They showed that over-
expression of the cluster compensates for reduced c-Myc levels. Tagawa et al (Tagawa, 
Karube et al. 2007) further strengthened this observation by parallel over-expression of c-
Myc and the cluster which resulted in more aggressive phenotypes displaying the 
synergistic relationship of those players. E2F1 itself is regulated by c-Myc and at the same 
time targeted by miR-17-5p and miR-20a. There appears to be complex auto-regulation 
between the E2F transcription factor family members (E2F1, E2F2, E2F3) and the miR-
17-92 cluster. Sylvestre et al (Sylvestre, De Guire et al. 2007) proved association of those 
transcription factors with the promoter region of the cluster, as well as their regulation via 
miR-20a binding sites in the respective 3´-UTRs of their mRNAs. 
 
 
Figure 1.2 Organization of ORF 25 located on chromosome 13. The miR-17-92 cluster 
can be found ~3.5 kb downstream of the locus promoter (first arrow). In front of this 
promoter, a c-Myc binding site and a binding site for E2F3 are located. Four exons 
constitute a transcript called MIRHG1 (microRNA host gene 1), the function of which is 
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unknown. Between the locus promoter and the predicted promoter (second arrow) 4 c-
Myc binding sites can be found. The cluster itself lies in the middle of the locus and is 
flanked by a polyadenylation site at its 3´ end. Further downstream another promoter 
element is predicted by NNPP v2.2 software (see text) followed by exon 4 of MIRHG1 
and the polyadenylation sequence of the locus. 
 
Very recently, p53 was found to negatively regulate cluster expression by binding next to 
the c-Myc site at the locus promoter and thus preventing c-Myc dependent activation of 
the cluster under hypoxic conditions (Yan, Xue et al. 2009).  
miR-17-92 is involved in many cancer types and has been shown to be over-expressed in 
lung cancers (Hayashita, Osada et al. 2005). The same group could show that inhibition of 
miR17-5p and miR-20a by antisense oligonucleotides leads to apoptosis in the respective 
lung cancer cells (Matsubara, Takeuchi et al. 2007). In accordance with its pathologic 
role, Lu et al (Lu, Thomson et al. 2007) showed the cluster´s expression during normal 
lung development in mice where it is naturally expressed in early stages and declines in 
later stages.  An over-expression in transgenic mice leads to elevated proliferation of lung 
epithelial cells and inhibition of differentiation. Carraro et al (Carraro, El-Hashash et al. 
2009) showed the role of the cluster in branching and budding morphogenesis during lung 
development due to direct targeting of Mapk14 and Stat3 mRNAs. Foshay and Gallicano 
confirmed the regulation of Stat3 by miR-17 family members and elaborated their role for 
embryonic stem cell differentiation (Foshay and Gallicano 2007). 
Further cancer types that have been shown to involve miR-17-92 cluster (dys)regulation 
are breast cancer (Hossain, Kuo et al. 2006; Yu, Wang et al. 2008), colon cancer 
(Diosdado, van de Wiel et al. 2009), and gastric cancer (Petrocca, Visone et al. 2008). 
There are several other known targets of miR-17-92 members. Shan et al (Shan, Lee et al. 
2009) showed targeting of fibronectin and fibronectin type-III domain containing 3A 
(FNDC3A) by miR-17, and targeting of thrombospondin-1 (Tsp1) and connective tissue 
growth factor (CTGF) was shown by Dews et al (Dews, Homayouni et al. 2006) who 
evaluated the miR cluster's role in tumor angiogenesis. Retinoblastoma protein 2 (Rb2) 
and p130 (another member of the same protein family) were shown to be targets of the 
cluster and implicate a role in adipocyte differentiation (Wang, Li et al. 2008). Regulation 
of cell cycle by miR-17 and miR-106b family members was shown by several groups. 
Cloonan et al (Cloonan, Brown et al. 2008) showed cell cycle-dependent expression of 
miR-17-92 in HeLa cells and increased proliferation of HEK293T cells after transfection 
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with plasmids overexpressing miR-17-5p. HEK293T cells show low endogenous 
expression of the cluster. Mitogen activated kinase 9 (MAPK9, aka JNK2) was one out of 
several targets the study confirmed. A more detailed study by Pickering et al (Pickering, 
Stadler et al. 2009) showed a role of the cluster in exact timing and integration of 
signaling events regulating the G1 checkpoint. Direct regulation of cell cycle regulator 
p21 (aka CDKN1A) was shown by Ivanovska et al (Ivanovska, Ball et al. 2008), Fontana 
et al (Fontana, Fiori et al. 2008), and could be confirmed by the author of this thesis in the 
cell line K562 (see manuscript 1). 
A number of studies on miR-17-92 revealed its role in malignant lymphomas. Recently it 
could be shown that the tumor suppressor PTEN and the pro-apoptotic protein Bim are 
direct targets of miR-17-92 (Xiao, Srinivasan et al. 2008). TP53INP1and FOXP1, 
amongst others, were shown to be affected in different B-cell lymphoma subtypes 
(Inomata, Tagawa et al. 2009). AML1 (Acute myeloid leukaemia-1, aka Runx1) controls 
differentiation of leukemia cells and was also shown to be regulated via miR-17-5p, miR-
20a and miR-106b (Fontana, Pelosi et al. 2007). A single study showed down-regulation 
of miR-17-5p in CLL (chronic lymphocytic leukemia) patients with TP53 abnormalities 
(Mraz, Malinova et al. 2009). Concerning the work presented here, we were interested in 
the relation of Pim-1 kinases (see below) that are over-expressed in several leukemia cell 
lines and the miR-17-92 cluster. 
 
1.4 RNAi with modified oligonucleotides and mirMimics 
RNA interference as a means of down-regulation of specific target mRNAs has been 
extensively used in recent years. Synthetic siRNAs and vector-based siRNA expression 
systems are available for efficient targeting approaches.  A relatively new method for 
specific and efficient down-regulation is usage of so-called miRNA mimics (McLaughlin, 
Cheng et al. 2007; Xiao, Yang et al. 2007). These are synthetic microRNAs in their 22-24 
nt dsRNA form, that are available commercially with (unspecified) modifications that are 
supposed by the manufacturers to confer increased metabolic stability on these molecules. 
In one of the studies mentioned above, miRNA mimics were encoded in triple 
combinations from a lentiviral vector and were used for targeting the Bcr-Abl 
oncoprotein. In the context of the work presented here, miRNA mimics were synthesized 
as single RNA strands and annealed in our lab. Compared to siRNAs, the annealed 
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miRNA duplexes are not fully base-paired, but rather contain the irregularities (bulges) of 
their natural counterparts. They were used here to mimic miR-33 expression in K562 cells 
for evaluating the miRNA´s role in targeting Pim-1 (see below).  
RNA interference with miR mimics itself is an appealing approach to abrogate 
dysregulated miRNA function in cancer and other diseases associated with over-
expression of microRNAs. In addition, so-called antagomirs were introduced by Krützfeld 
et al (Krutzfeldt, Rajewsky et al. 2005) who coupled cholesterol to ssRNA analogues (2´-
OMe-modified) complentary to miRNAs. Those antagomirs were efficient in silencing 
miR-122 in in vivo models. Antagomirs are 100 percent complementary to the targeted 
miRNA and are supposed to act through permanent target-binding. Efficiency of this 
approach has also been proved by Cheng et al (Cheng, Byrom et al. 2005) in evaluating 
miRNAs involved in cell growth and apoptosis.  
To further improve binding capacities and silencing efficiency, several oligonucleotide 
modifications have been introduced into anitimiRs. Most promising results have been 
shown for locked nucleic acids (LNAs). In those molecules a methylene bridge connects 
the 2´-oxygen of ribose with the 4´-carbon (see fig 1.2 for a comparison of different oligo 
modifications (taken from Ref. (Braasch and Corey 2001)). LNA-modified oligos are very 
stable against cleavage by endo- and exonucleases (Grünweller and Hartmann 2007). On 
the other hand it has been shown that so-called LNA gapmers (containing an unmodified 
DNA stretch in the middle) can recruit RNases. LNA gapmers cause cleavage of target 
molecules due to a recruitment of RNase H (Kurreck, Wyszko et al. 2002) in vitro, and it 
may be possible that other RNases are recruited in human cells. 
LNA-antimiRs have already been used successfully in primate gene delivery approaches 
(Elmen, Lindow et al. 2008). It could be shown that miR-122 function was silenced, 
restoring normal aldolase A expression and respective cholesterol levels in African green 
monkeys without any associated toxicity. Yet another study claimed profound 
hepatotoxicity for LNAs, and the effects were shown to be independent of targets 
(Swayze, Siwkowski et al. 2007). Irrespective of those contradicting in vivo outcomes, 
LNAs offer a valuable tool for in vitro RNA interference and were used in this work for 
inhibition of miRNA function. 
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Figure 1.3 Different oligonucleotide modifications are shown that can be used in RNA 
interference applications. For this study, LNA modifications are relevant. Taken from 
Braasch and Corey, 2001. 
 
1.5 Detection of microRNA expression 
MicroRNAs can be detected by several means. On the one hand, high throughput methods 
such as micro-arrays or 454 sequencing are available (Hafner, Landgraf et al. 2008; Wark, 
Lee et al. 2008). Those methods are rather expensive and data analysis calls for respective 
resources and tools, albeit new tools that integrate databases were published very recently 
(Hackenberg, Sturm et al. 2009). On the other hand, classical methods such as Northern 
blot analysis are used to detect single microRNAs (e.g. in (Hayashita, Osada et al. 2005)) 
where no large scale profiling is necessary. Improvements to Northern blots were 
provided by introducing LNA (locked nucleic acid) modifications to probes (Valoczi, 
Hornyik et al. 2004; Varallyay, Burgyan et al. 2007). Northern blots require high amounts 
of starting material, so PCR-based methods may be more suitable. Chen et al. (Chen, 
Ridzon et al. 2005) introduced a technique that relies on intricate primer design and 
reverse transcription. A universal stem-loop primer for reverse transcription is used that 
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base pairs with its unique (complementary) 3´end to the mature miRNA 5´end. Reverse 
transcriptase can then elongate the looped primer over the whole length of the mature 
miRNA. A real time PCR follows where one primer is the sequence of the mature 
microRNA and a second universal reverse primer has the sequence of the 5' end of the 
stem-loop primer used for reverse transcription. The aim of this approach is to increase 
the length of the resulting PCR amplificate for easy detection with standard real time PCR 
settings (e.g. SYBR Green). Otherwise, a 20-30 bp segment cannot be amplified via PCR. 
At the same time the assay provides a specificity step due to the fact that the stem-loop 
with its 3´overhang only base pairs with an end of the respective miRNA and no other 
RNAs (i.e. because of steric hindrance). Chen´s approach has already been multiplexed 
for analysis in single cells (Tang, Hajkova et al. 2006) and can also be used in 
combination with detection of precursor miRNAs (Schmittgen, Jiang et al. 2004; 
Schmittgen, Lee et al. 2008). In the presented thesis, this approach was chosen because of 
easy, reliable and straightforward implementation. 
Several other methods have been introduced to the field, such as splinted ligation that has 
no amplification step and is claimed to be more sensitive than Northern blot analysis, but 
nevertheless is based on usage of radioactively labeled probes (Maroney, Chamnongpol et 
al. 2007). Padlock probe rolling circle amplification and quantitative primer extension 
PCRs also rely on amplification steps (Raymond, Roberts et al. 2005; Jonstrup, Koch et 
al. 2006). The latter method is similar to the stem-loop approach, albeit here no loop is 
formed, but just a shorter universal sequence is added to a complementary sequence that 
pairs with mature miRNA 3´ end. 
 
1.6 Pim-1 kinase 
Pim kinases (Pim – proviral integration site for moloney murine leukemia virus; Pim-1, -
2, -3) belong to the family of Serine/Threonine kinases. They are categorized as classical 
proto-oncogenes and have been shown to be over-expressed in several tumors, especially 
prostate cancers and hematopoietic disease (Chen, Chan et al. 2005; Dai, Li et al. 2005; 
Hammerman, Fox et al. 2005; Xu, Zhang et al. 2005; Chen, Limnander et al. 2008), and 
appear to be involved in malignant transformation. Their anti-apoptotic action can be 
assigned to phosphorylation and thus functional modulation of proteins like Bad or p21, 
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both molecules involved in cell-cycle regulation. In summary, they stimulate cell 
proliferation and inhibit apoptosis. 
Pim-1 is the best known family member and involved in the development of B-cell 
lymphomas. Synergism between Pim-1 and the transcription factor c-Myc has been shown 
to play a role in this respect (Zippo, De Robertis et al. 2007; Zhang, Wang et al. 2008). 
Pim-1 kinases are constitutively active kinases and phosphorylate e.g. Cdc25A 
(Mochizuki, Kitanaka et al. 1999), and Cdc25C (Bachmann, Kosan et al. 2006), p21 
(Wang, Bhattacharya et al. 2002), HP1γ (Koike, Maita et al. 2000), Bad (Aho, Sandholm 
et al. 2004), Tudor SN (Leverson, Koskinen et al. 1998) and others (for review see 
Bachmann and Möröy, 2005). 
Interestingly a knockout of all three Pim kinases in parallel in mice caused no substantial 
effects in development and fertility of those animals. A reduction in body size at birth and 
throughout postnatal life and an impaired response to growth factors (Mikkers, Nawijn et 
al. 2004) were reported. This offers potential for therapeutic interventions in vivo, as side 
("off-target") effects on healthy tissues and cells are expected to be low. 
Pim-1 promotes polyploidy and leads to genomic instability as shown by Roh et al. (Roh, 
Gary et al. 2003; Roh, Franco et al. 2008). This is reflected in a mitotic spindle checkpoint 
defect and somehow mediated by posttranscriptional regulation of cyclin B1, as the 
protein levels of this cell cycle regulator follow Pim-1 levels. Effects of this Pim-1 
dependent polyploidy on the expression of cell cycle regulators or microRNAs need 
further investigation. It is not clear, how this effect on polyploidy influences the 
differentiation of those cell lines and their long term existence as a distinct line.  
The pro-apoptotic protein Bad is phosphorylated by Pim-1 and Pim-2 (Yan, Zemskova et 
al. 2003; Aho, Sandholm et al. 2004). Pim-dependent phosphorylation of serine 112 
results in cytoplasmic sequestration of Bad by its binding to the 14-3-3 protein, which 
suppresses apoptosis by preventing interaction of Bad with Bcl-xL and thus cytochrome c 
release from mitochondria (Macdonald, Campbell et al. 2006). P21, another important 
target of Pim-1, can arrest the cell cycle at different stages by binding to several cyclin-
dependent kinases (cdk) or to the proliferating cell nuclear antigen (PCNA) to block 
replication (Li, Waga et al. 1994; Waga, Hannon et al. 1994; Gartel 2005; Gartel and 
Radhakrishnan 2005). In human lung carcinoma cells Pim-1 was reported to 
phosphorylate p21 at Thr145 (Zhang, Wang et al. 2007). This phosphorylated form of p21 
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localizes to the nucleus, where it is thought to sterically interrupt the interaction of p21 
with PCNA, which then relieves the p21-mediated blockage of the DNA synthesis 
machinery (Rossig, Jadidi et al. 2001; Zhang, Wang et al. 2007).  
Expression of Pim-1 is mainly regulated at the transcriptional level by the action of 
several interleukins and growth factors that activate STAT3 and/or STAT5 via Janus 
kinases (Heinrich, Behrmann et al. 2003; Bachmann and Moroy 2005). In addition, the 
transcription factor Kruppel-like factor 5, which can be expressed after induction of DNA 
damage, represses Pim-1 expression in the p53-deficient cell line HCT116 by binding to 
the Pim-1 promoter, thus favoring apoptosis (Zhao, Hamza et al. 2008). In B cells CD40 
signaling regulates the expression of Pim-1 kinase via the NF-kappaB pathway (Zhu, 
Ramirez et al. 2002). 
Pim-1 protein stability is controlled by the heat shock proteins Hsp90 and Hsp70 as well 
as the phosphatase PP2A (Losman, Chen et al. 2003; Shay, Wang et al. 2005; Ma, Arnold 
et al. 2007). Hsp90 increases the half-life of Pim-1 by protecting it from proteasomal 
degradation, whereas Hsp70 can mediate Pim-1 degradation (Shay, Wang et al. 2005). 
The prolyl-isomerase Pin1 is thought to mediate binding of phosphorylated Pim-1 to the 
regulatory subunit B56-beta of PP2A, leading to dephosphorylation by the catalytic 
subunit of PP2A followed by ubiquitinylation and degradation of Pim-1 via the 
proteasome (Ma, Arnold et al. 2007). Pin1 is thus redundant with Hsp70´s function in 
reducing Pim-1 half-life.  
 
 
Figure 1.4 Pim-1 mRNA. MicroRNA binding sites as predicted by TargetScanHuman 5.1 
are shown. Those binding sites relevant to the thesis presented are highlighted. 
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Figure 1.5 Pim-1 kinase interacts with c-Myc at several loci in the genome, which may be 
relevant also at the miR-17-92 locus (see text). Interactions with HP1γ may cause 
chromatin rearrangements effecting expression at the locus Chr13Orf25. Pim-1 
knockdown (b) could exert effects through altering the phosphorylation state of HP1γ and 
resulting downstream regulatory events.  
 
1.7 Projects 
 
This work aimed at evaluating the relationship between Pim-1 expression and miR-17-92 
cluster expression in K562 cells, as well as putative effects of the cluster. Also, the 
regulation of Pim-1 itself (by miRNAs) was investigated. For this, several questions had 
to be answered. First, is there a direct link between cluster expression and Pim-1 protein 
level? What are the effects of the microRNAs from the cluster? Can a targeting of mature 
microRNAs of the cluster revert the proliferative phenotype of K562 cells? As Pim-1 
plays a prominent role in different cancers and especially in leukemias (see introduction), 
what microRNAs may be involved in down regulation of Pim-1, and thus are probably not 
expressed in Pim-1 over-expressing cells? 
Different cancer cell lines were profiled for miR-17-92 and Pim-1 expression as well as 
for a few other miRNAs (e.g. miR-15/16/33/124/144) that seemed to be interesting 
candidates regarding Pim-1 regulation. To evaluate regulation of Pim-1 by microRNAs, 
its 3´-UTR was cloned and miR-15/16 and miR-33 binding sites were mutated. A 
pGL3control vector was used with the 3´-UTR fused to the end of a luciferase gene. 
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Regulation was evaluated by applying miR-33 mimics and monitoring luciferase 
expression of the reporter constructs (fig 1.6). 
 
 
 
Figure 1.6 Expression vector “pGL3 control” with cloned Pim-1 3´-UTR. Mutation of 
miRNA target sites is a standard procedure for evaluation of miRNA-binding. Interference 
of either cellular miR-33 or transfected miR-33 mimics are depicted. 
 
Furthermore, the targeting of mature microRNAs by LNA-antimiRs was evaluated in this 
work. For this reason, several sizes of LNA antisense oligonucleotides were tested against 
miR-let-7 using a pGL3control luciferase vector system containing a fully complimentary 
let-7 target site downstream of the luciferase gene. The p21 3´-UTR was then used as a 
further test system accompanied by direct detection of cellular p21 protein level after 
antimiR-17 targeting using Western blot analysis. 
It is interesting that the miR-17-92 cluster is flanked by a predicted promoter and a 
polyadenylation site at its 3´ end. This could mean that the cluster is expressed as an 
independent transcription unit, compared to transcription from the main locus 
(chromosome 13, open reading frame 25), so to speak there may be circumstances, e.g. 
stress, under which such kind of regulation would be important. Expression of the miR-
17-92 locus was analyzed after Pim-1 knockdown (via standard siRNAs) using qRT-PCR 
analysis. To address the question if Pim-1 alters expression differently at regions within 
the locus, i.e. at the predicted promoter, several sites for quantification were chosen 
(figure 1.7). To further evaluate the role this internal promoter region immediately in front 
of the cluster, segments of different size out of this region were cloned into a reporter 
miR-33 target sequence (seed) CAATGCAA         
was mutated to CAgTGCgA 
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vector upstream of a luciferase gene. Putative TATA-boxes were mutated in order to infer 
effects from altered promoter activity (figure 1.8).  
 
 
Figure 1.7 Regions within the miR-17-92 cluster locus are shown that should be 
addressed and quantified with qRT-PCR experiments under Pim-1 knockdown conditions. 
 
 
Figure 1.8 Internal promoter region of the miR-17-92 cluster. The magnified region can 
be divided into two parts. The first part is a GC-rich region (>80%) that ends 1.4 kb 5´ to 
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the miR-17-92 cluster. Within this region four c-Myc binding sites and exons 2 and 3 of 
MIRHG1 are located. The GC-rich region is followed by an AT-rich region (~70%) that 
contains the predicted promoter with two non-consensus TATA-boxes (red boxes). They 
were mutated and the respective construct was analyzed in luciferase promoter assays.  
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2 Methods 
All methods, constructs and sequences are outlined in the manuscripts of this thesis. Here 
just some additional information is provided. 
2.1 Bacterial cell culture and transformation 
E. coli cells were cultured at 37°C in LB medium at 220 rpm in a lab shaker. LB medium 
was prepared as follows: 
 
LB medium  
Yeast extract 5 g/l 
Pepton 10 g/l 
NaCl 10 g/l 
Agar agar 15 g/l (only for plates) 
 
After preparation, media were autoclaved at 121°C and 1 bar for 20 min in an autoclave 
and stored at room temperature. Handling of bacteria was performed sterile by working 
near the flame of a Bunsen Burner. E. coli DH5α were used for plasmid maintenance. E. 
coli cells were selected according to the respective resistance gene/plasmid with a 
concentration of 100µg/ml of the respective antibiotic. Agar plates were poured into 7.5 
cm dishes after the Agar was cooked at 100°C and cooled down to ca. 60°C when 
antibiotics were added. Plates were stored for max. 4 weeks at 4°C. Stocks of bacteria 
were built from overnight cultures. 500 µl bacteria were mixed with 500 µl autoclaved 
glycerol and put into liquid nitrogen. After this procedure, stocks were stored at -80°C. 
 
2.2 Preparation of chemically competent E. coli DH5α cells  
Preparation was done with the help of my co-worker Dan Li and application of her 
protocol for this, which is taken from her PhD thesis and outlined below. 
“To prepare chemically competent E. coli DH5αcells, the calcium chloride method was 
used. This chemical treatment requires no special equipment and gives 105-106 
transformants per microgram DNA. As the strain DH5α is devoid of any antibiotic 
resistance, cells were handled with particular care during this procedure to avoid 
contamination. 
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DH5α cells were first spread from a glycerol stock stored at -80°C onto an LB agar plate 
and incubated at 37°C for around 16 h. A single freshly developed colony was inoculated 
into 3ml of LB medium and was grown at 37°C overnight or for at least 6 h in a shaking 
incubator. Afterwards, 2.5 ml of the culture were transferred into 500 ml of fresh LB 
medium and further grown until the OD578 reached 0.5-0.6, which took about 4 h. Cells 
were transferred into two centrifuge bottles and, after cooling on ice for 10 min, harvested 
at 4,000 rpm (Eppendorf 5810R centrifuge) for 15 min at 4°C. Each cell pellet was 
suspended in 50 ml of ice-cold 100 mM CaCl2 solution and transferred into two 50 ml 
tubes kept on ice. Cells were pelleted once more at 7,000 rpm (Eppendorf 5810R) for 10 
min at 4°C. Each cell pellet was suspended in 7 ml of ice-cold CaCl2 solution (75 mM, 
25% (v/v) glycerol). Finally, aliquots were prepared in vials placed on ice, frozen in liquid 
nitrogen and stored at -80°C. The frozen competent cells could be stored for up to 1 year 
without substantial loss of transformation efficiency.” 
 
2.3 Transformation of chemically competent E. coli 
Bacteria were taken from -80°C thawn on ice. 50 µl of bacteria were transferred into 1,5 
ml tube and 5 µl of ligation reaction, or plasmid dilution (e.g. 1:1000) were added to the 
bacteria. The mixture was incubated 30 min on ice followed by 45 seconds at 42 °C. Cells 
were then incubated for 2 min on ice. After this 300 µl LB-medium (without antibiotics) 
was added and incubate for 60 min at 37°C at 200 rpm in an Eppendorf thermomixer. 
Cells were centrifuged and 250 µl of LB medium was discarded. The remaining volume 
was used for resuspending the cells and plating. After plating incubation was done over 
night at 37 °C in a standard incubator. 
 
2.4 Cloning 
2.4.1 Cloning of 3´UTRs and putative miR-17-92 promoter regions 
3´UTRs and miR-17-92 promoter regions were cloned from genomic DNA of K562 cells. 
Preparation of gDNA was done with Qiagen´s DNeasy Blood & Tissue Kit according to 
manufacturer´s protocol. Amplification procedure was as follows: 
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PCR reaction  
gDNA 300 ng 
10x Taq buffer with KCl 5 µl 
dNTP mix (each 2.5 mM) 1 µl 
Primer 1 (100 µM) 0.5 µl 
Primer 2 (100 µM) 0.5 µl 
25 mM MgCl2 2 µl 
Taq Polymerase 2.5 units 
water Adjust to 50 µl 
 
PCR program, 30 cycles (step 2-4) 
step temperature time 
1 94°C 5 min 
2 94°C 45 s 
3 56°C 1 min 
4 72°C 90 s 
5 72°C 7 min 
6 10°C pause 
 
The PCR fragments were purified using Quick Spin columns (Qiagen) and restricted with 
respective enzymes (see manuscripts). Restriction reactions were performed at 37°C for 2 
hours. After this, fragments were purified with a crystal violet gel. The bands were 
excised and cleaned with Qiagen PCR purification kit or Promega´s “Wizard SV Gel and 
PCR Clean-Up System” according to manufacturer´s instructions. 
 
Crystal violet gel  
Crystal violet (10 mg/ml in TBE) 1:1000 dilution 
TBE buffer 1x 
Agarose 1-2.5 % 
 
Running buffer for crystal violet gels is TBE containing 10 µg /ml of the dye 
 
Plasmids were restricted with respective enzymes and dephosphorylated using Fermentas 
CIAP enzyme.  
 
Dephosphorylation reaction  
10 µg vector X µl 
10x buffer 5 µl 
5 u CIAP 5 µl 
adjust to 50 µl 
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The reaction was incubated for 30 min at 37°C. After this another 3 units of enzyme in a 
volume of 30 µl were added and followed by incubation step of 30 min at 50°C.  Finally 
another 2 units of enzyme were added in a volume 20 µl and incubated for 30 min at 
37°C. 
Vector was purified with a QIAquick Spin column. For ligation reaction, amount of 
restricted vector and fragment was calculated according to the formula1: 
 
MassFragment [ng] = 5 x MassVector [ng] x LengthFragment [bp] / LengthVector [bp] 
 
Ligation reaction included: 
 
Ligation reaction  
insert X µl 
vector X µl 
10x reaction buffer A 1 µl 
T4 DNA Ligase 10 units 
Adjust with water to 10 µl 
 
Ligation program  
37°C 30 min 
30°C 30 min 
25°C 30 min 
20°C 30 min 
16°C 3 h 
20°C 2 h 30 min 
25°C 2 h 30 min 
30°C 30 min 
16°C 13 h 
16°C pause 
 
2.4.2. Mutation of miRNA binding sites in 3´UTRs and mutation of promoter                   
regions 
Mutagenesis PCR was applied for mutation of putative promoter regions as well as 
annotated miRNA binding sites. Primers were designed according to references (see 
respective manuscripts).  pGL3 control vector containing the respective constructs were 
used as templates in the mutagenesis PCR reaction. The forward primer contained the 
                                                            
1 Cornel Mühlhardt, Der Experimentator: Molekularbiologie/Genomics 4. Auflage, Spektrum Akademischer 
Verlag, Berlin 2003 
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base exchanges needed to interfere with function of the respective site. A complementary 
reverse primer was designed and used in the PCR reaction. Primers were physphorylated 
using T4 PNK (Fermentas). Phosphorylation reaction was performed for 1 h at 37°C with 
subsequent heat inactivation at 70 °C for 5 min. Subsequent PCR reaction was done with 
Pfu DNA Polymerase from Fermentas. 
 
Phosphorylation reaction mix  
Primer (100 µM) 5 µl 
10x buffer A (for forward reaction) 2.5 µl 
10 mM ATP 2.5 µl 
T4 PNK 10 units 
Adjust with water To 25 µl 
 
Mutagenesis PCR reaction  
10x Pfu buffer with Mg2SO4 10 µl 
dNTPs, 2.5 mM  1.6 µl 
First primer phosphorylated 2.5 µl 
Second primer phosphorylated 2.5 µl 
template 100 ng 
Mg2SO4 25 mM 12 µl 
Adjust with water to 100 µl 
 
Mutagenesis PCR program, 15 cycles (step 2-4) 
step   
1 95°C 5 min 
2 95°C 1 min 
3 50°C 90 s 
4 72°C 14 min 
5 72°C 10 min 
6 8°C pause 
 
50 µl of a mutagenesis PCR were then restricted with DpnI to get rid of the unmutated 
template plasmid. For this 1 unit DpnI were added while the total reaction volume was 
adjusted to 60 µl with water and respective buffer. After incubation for 1 h at 37°C 
another 10 units of enzyme were added and again incubated for 1 h at 37°C. Volume of 
the reaction was reduced to ca. 10 µl by using a speed-vac centrifuge at 50°C for 1 h. For 
transformation of chemically competent bacteria 2 µl of the reaction was added in the 
respective step. 
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2.5 Plasmid preparation 
Plasmid mini preparation was done using Ferments GeneJET Plasmid Miniprep Kit. Maxi 
Preps were done with Qiagen´s EndoFree Plasmid Maxi Preparation Kit. All preparations 
were performed according to the manufacturer´s instructions. All constructs generated 
were sequenced at Eurofins MWG Operon and manually checked for mutations using 
EMBL-EBI tool pairwise alignment (http://www.ebi.ac.uk/Tools/emboss/align/). 
 
2.6 Animal cell culture and transfection procedures 
2.6.1 Cell culture 
Cells were cultured at 37°C and 5 % CO2 in a humidified incubator. Handling of cells was 
done in a sterile bench. The K562, Hela, H69 and H209 cells were cultured in RPMI 1640 
(PAA) supplemented with 10 % FCS (PAA). All other cell lines were cultured in IMDM 
containing 10 % FCS. Freeze down of cells was done in the respective medium 
supplemented with 20 % FCS and 5 % DMSO. For this cells were centrifuged for 5 min at 
2050 rpm and supernatant was discarded. After resuspension of the cells in 1 ml freeze 
down medium, cells were transferred to 2 ml tubes and packed into a styrofoam box filled 
with paper towel. The box was put to -80°C for at least 24 hours. After this, cells were 
stored in liquid nitrogen for longer periods. 
   
2.6.2 Electroporation of K562 cells 
Cells were harvested from tissue culture flasks (75 cm2) and transferred to 50 ml tubes. 
They were centrifuged at 2050 rpm in a Hettich universal 320 centrifuge at room 
temperature for 5 min. Supernatant was discarded and the cell pellet washed with 10 ml 
RPMI 1640. Cells were centrifuged again under the same conditions and resuspended in 
2.5 ml RPMI 1640 per flask. Cells were counted and adjusted (via another centrifugation 
step) to a concentration of 1*106 cells / 50 µl with RPMI 1640. 100 µl of cell-suspension 
was transferred into a 4 mm BioRad GenePulser cuvette and mixed with an appropriate 
amount of nucleic acid (e.g. 2 µg siRNA per 1 million cells) by gently pipetting up and 
down two times. Electroporation was then performed with a single pulse in a Biorad 
GenePulser XCell using a square wave protocol (330V, 10ms). Electroporated cells were 
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immediately transferred into a well of a 12-well-plate supplemented with 1.5 ml medium 
if not indicated otherwise. 
Cuvettes were used up to 8 times. For this, cuvettes were rinsed with 70 % Ethanol and 
stored in 70 % ethanol for at least 1 day. After this cuvettes were rinsed with 
demineralized water and sonicated in demineralized water for 15 min in a Branson 
Sonifier 250 using the settings “output control” between 2-3 and “Duty” between 20-30. 
Subsequent to sonification, cuvettes were rinsed with demineralized water again and 
finally stored in 70 % ethanol for at least 1 day. Cuvettes were then dried for several hours 
under a sterile bench. 
 
2.7 Luciferase Assay 
Luciferase Assays were performed using the Promega Luciferase Assay System. Cells 
were transfected with 5µg / 1 Mio cells of the pGL3 control vector. For RNAi 
experiments, nucleic acids were co-transfected. Contructs were cloned either to the XbaI 
site at the end of the luciferase gene (e.g. 3´UTRs) or in front of the reporter by removing 
the SV40 promoter by HindIII/BglII restriction (mir-17-92 Promoter assays). If not 
indicated cells were harvested after 48 hours by centrifugation at 4°C and 2500 rpm in a 
table centrifuge for 5 min. Cells were then lysed using 100 µl of reporter lyses buffer per 1 
Mio cells by pipetting up and down and shaking incubation in a tabletop shaker for 30 min 
at room temperature. Then 10 µl of lysate were transferred into a well of a white 96-well 
plate and mixed with 10 µl of substrate solution. This was done in triplicates. 
Luminescence was measured with a Safire II multiformat platereader (Tecan) using the 
following settings: 
 
Measurement mode: Luminescence 
Integration time (Manual): 10 ms 
Plate Definition file: GRE96fw.pdf 
Shake duration (Orbital Medium): 3 s 
 
Measurement was performed 2 times immediately after one another, to ensure a more 
homogenous mixing. Second measurement was taken for data analysis.  
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2.8 Western blot analysis 
Cell transfection was performed as described. For Western blot analysis, cells were 
centrifuged in a table centrifuge for 5 min at 2500 rpm at 4 °C. Supernatant was removed 
and cells were lysed in lysis buffer: 
 
Lysis buffer  
Tris HCl 125 mM, pH 6.8 
SDS 4 % 
2-Mercaptoethanol 1.4 M 
Bromphenolblue 0.05 % 
 
1 Mio cells were lysed in 100 µl buffer by vortexing 10 s and heating to 95°C for 5 min in 
a standard heating block. Lysates were stored at -20°C. 20 µl of each lysate was loaded to 
a Polyacrylamid Gel (PAGE). 
 
Preparation of Gels (0.75 mm) 
If not indicated, 15 % gels were used. 
Separation gel for 2 gels 
Buffer 1,5 M Tris HCl,  pH 8.8 0,6 % SDS 4 ml 
30 % PAA 8 ml 
Deminarlized water 4 ml 
APS 10 % 80 µl 
TEMED 20 µl 
 
Collecting  gel for 2 gels 
0,5 M Tris HCl,  pH 6,8 0,6 % SDS 1,8 ml 
30 % PAA 1 ml 
Deminarlized water 4,7 ml 
APS 10 % 24 µl 
TEMED 9 µl 
 
Gels were run for 1 h at 180 V using a Mini-Protean system (Bio-Rad) in 1x running 
buffer (SDS Page Laufpuffer, Roth). Transfer of gels was done in a semi dry blotter 
(C.B.S. Scientific). For this, Immobilon-P membranes (Millipore) with a pore size of 0.45 
µm were prepared as follows:  
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A single membrane was incubated for 15 s in methanol and washed in water for 2 min. 
Until assembly gel, membrane and whatman paper was incubated with transfer buffer. 
 
Transfer buffer 
25 mM Tris HCl, pH 8.3  
192 mM Glycin  
10 % Methanol 
 
 
Figure 2.1 Assembly of gel blotting system 
 
Transfer was run for 90 min at 1 mA per cm2 membrane using an EBU-4000 blotter 
(C.B.S. Scientific). After transfer, blots were incubated for 2 hours with 5 % milk pouder 
solution in TBST. Blots were then washed three times with TBST for 10 min. Incubation 
and dilution of antibodies can be found in the respective manuscripts. Each blot was 
incubated with Amersham ECL Western blotting reagents according to the manufacturer’s 
protocol. Substrate incubation was performed for 2 minutes. For detection, Kodak 
BioMax Light Films, Kodak GBX developer/replenisher and GBX fixer/replenisher were 
used.  
 
TBST  
Tris HCl 10 mM, pH 7.6 
NaCl 150 mM 
Tween 20 0.1 % 
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2.9 Nucleic acid methods 
2.9.1 Agarose gels 
Gels were prepared using TBE buffer. Agarose was used in a range from 0.5 % - 2.5 %. 
For 100 ml of gel, the respective amount of agarose was added to a glass flask and 
adjusted to a total volume of 100 ml. After cooking in a conventional microwave, 
ethidium bromide (Roth) was added according to manufacturer´s instructions. Gels were 
run at 120 mA for 1 h.  
As markers 2-log ladder from NEB and 10 bp ladder from Invitrogen were used according 
to manufacturer´s instructions. For sample loading, a loading buffer was used at a final 
concentration of 1x. 
 
5x DNA loading dye  
Glycerin 70%  
EDTA 50 mM 
Tris HCl 100 mM, pH 7,5 
Bromphenolblue 0.05 %  
Xylencyanolblue 0.05 % 
 
Gels were visualized in a Bio-Rad gel documentation system (Biostep Transilluminator) 
under UV-light. 
 
2.9.2 RNA preparation 
RNA preparation was done using the RNeasy Mini Prep Kit (Qiagen) or the RNeasy Mini 
Plus Prep Kit (Qiagen) according to manufacturer´s instructions. The latter kit contains 
gDNA removal columns. In combination with the former kit an optional on column 
digestion of gDNA was done according to manufacturer´s protocol using the 20 units 
TURBO DNase (Ambion) in a total volume of 80 µl. 5 Mio cells K562 were used for 
preparation with a single column. RNA concentration was determined with a standard 
photometer (Biomate3, Thermo). Samples were measured three times as 1:100 dilutions in 
water. For purification of mature miRNAs Ambion´s mirVana miRNA Isolation Kit was 
used according to manufacturer´s instructions for enrichment of small RNAs. Also 5 Mio 
K562 cells were used for one column. 
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A second RNA preparation protocol was used as well. For this, classical 
phenol/chloroform extraction was performed. Acid phenol was prepared by shaking an 
appropriate volume of phenol with 1/10 volume 1x TE buffer. The upper liquid phase was 
discarded and the remaining phenol was 3 times shaken with 1/10 volume sodium acetate 
(300 mM, pH 5) and liquid phase was discarded each time. Cell pellets were resuspended 
and lysed using the respective buffer of Qiagen´s RNeasy Kit and the protocol above. One 
volume of acid phenol was added to the lysed cells and shaken at room temperature for 5 
min followed by 5 min centrifugation (13000 rpm, 4°C). The upper liquid phase was 
transferred to a new tube and an equal volume of chloroform was added and shaken at 
room temperature for 5 min. A second centrifugation was followed by transferring the 
upper liquid phase to a new tube. An ethanol precipitation was done as follows: 1/10 
volume sodium acetate (300 mM, pH 5) was added as well as 2.5 volumes of ethanol. The 
mixture was set to -20°C for 30 min to 24 hours. Then a centrifugation step at 13000 rpm 
(4°C) for 30 min followed. Supernatant was discarded and the pellet dried at room 
temperature for 5 min. The pellet was resuspended in 30 µl H2O. To get rid of DNA 
contamination, a digestion with TURBO DNase from Ambion was done using 20 units 
and incubation at 37°C for two hours. A second acid phenol/chloroform extraction was 
done as described above. 
 
2.9.3 Concentration of nucleic acids 
For transfection experiments amounts of nucleic acids (siRNAs, LNAs, etc.) were 
calculated with the formula2 : 
 
c [µg/ml] ÷ MW of nucleic acid [g/mole] x 10-6 g/µg x 103 ml/l = c [M] 
 
Concentrations of nucleic acids in solution were measured in triplicates as 1:100 dilutions 
in water with a Biomate 3 photometer (Thermo). For DNA absorption 260/280 was used 
to also determine purity/protein contamination. 
 
 
                                                            
2 Dany Spencer Adams, Lab math: A handbook of Measurements, Calculations, and other Quantitative Skills for 
use at the bench, Cold Spring Harbour Laboratory Press 2003 
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2.9.4 RT-PCR 
The Fermentas RevertAid H Minus First Strand cDNA Synthesis Kit was used according 
to manufacturer´s instructions. In short, for one RT-PCR reaction 1 µg of RNA was used 
with 1 µl of random hexamer primer (provided in the kit). For reverse transcription of 
mature miRNAs 1 µl of looped primer (100 µM) was used. Looped primers were designed 
according to references [see manuscripts]. As an example for a looped RT-primer you can 
see the design for miR-20a below: 
  
5´-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACctacctg-3´ 
Looped primer for miR-20a 
 
5´-uaaagugcuuauagugcagguag-3´ 
Mature miR-20a 
 
Capital letters indicate the universal part of the primer. Boxes indicate base pairing 
between those regions so that the primer forms a stem-loop structure with a 3´overhang 
which is complementary to the targeting strand of the mature miRNA (indicated bold). In 
a standard PCR cycler the following program was used: 
RNA and primer are mixed and adjusted to 11 µl with water. They are incubated for 5 min 
at 80°C and put on ice after this. RiboLock Ribonuclease Inhibitor provided in the kit is 
not used as it negatively influences the subsequent QT-PCR reaction. The following 
components are added as one mix: 
 
5x reaction buffer 4 µl 
10 mM dNTP mix 2 µl 
Water 2 µl 
 
Then reaction is incubated for 5 min at 25°C. After addition of 1 µl RT enzyme (=200 
units) 10 min of incubation at 25°C are followed by 60 min at 42°C. Finally the reaction is 
stopped by heating at 70°C for 10 min and cooling down to 8°C. cDNAs were stored at -
20°C. 
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2.9.5 QT-PCR 
Quantitative real time PCR was performed using a Roche LightCycler 2.0 with Software 
Version 4.05 and the Absolute QPCR SYBR Green Capillary Mix (Thermo Fisher). Each 
sample was measured in triplicates. For this the following components were mixed: 
 
2x capillary mix 15 µl 
Primer pair (5 µM each) 6 µl 
Water 3 µl 
 
7.2 µl of cDNA (1:10 dilution for standard RNA, 1:100 dilution for enriched miRNAs) 
are added to the mix. After mixing by pipetting up and down 10 µl are transferred to a 20 
µl glas capillary (Roche). Via a pre-cooled adaptor (Roche) capillaries are centrifuged for 
5 s at 2000 rpm in tabletop centrifuge and put into a cycling rotor. Cycling is carried out 
as follows: 
Initial activation of polymerase for 15 min at 95°C followed by 
 
40 cycles of amplification  
temperature time 
95°C 10 s 
55°C 20 s 
72°C 12 s 
 
Fluorescence acquisition is measured at 72°C in the single measurement mode. 
 
Melting curve  
temperature time 
95°C 0 s 
57°C 15 s 
98°C 0 s 
 
Fluorescence acquisition was measured at 98°C in the “continues” measurement mode. 
For a detailed example see appendix. Data were analyzed with the 2-∆∆CT  method [see 
manuscripts for reference].  
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Abstract  
 
The proto-oncogene Pim-1, an anti-apoptotic kinase that acts synergistically with c-Myc to 
promote tumorigenesis, is overexpressed in the human myeloid leukemia cell line K562. In 
this study siRNA-mediated knockdown of Pim-1 revealed cell proliferation to be Pim-1-
dependent, with a role of Pim-1 in the transition from mitosis to G1-phase of the cell cycle. 
We further re-analyzed the effects of the phosphatase PP2A inhibitor okadaic acid (OA): 
PP2A is involved in Pim-1 degradation and its inhibition is known to increase Pim-1 levels; 
also, PP2A can induce apoptosis by dephosphorylation of the pro-apoptotic protein Bad, 
which is a phosphorylation target of Pim-1. OA-treatment induced a series of so far unnoticed 
dynamic changes: a short-term increase of Pim-1, followed by its rapid and unexpected 
complete down-regulation. OA-induced disappearance of Pim-1 was accompanied by a strong 
but transient induction of the cell cycle inhibitor p21 and a switch from proliferation to 
apoptosis. RNAi-mediated knockdown of p21 delayed this onset of apoptosis in OA-treated 
K562 cells. Although untreated growing K562 cells are p21-deficient, substantial amounts of 
p21 mRNA are detectable. We found that translation of p21 in K562 is completely repressed 
by microRNAs miR-17-5p and miR-20a and could be specifically derepressed by transfection 
of short, seed-directed all-LNA AntimiRs. OA treatment increased the basal p21 mRNA 
levels approx. 10-fold, and these induced levels persisted despite microRNA-independent 
disappearance of the p21 protein at later time points. We conclude that tight miR-17-5p/-20a-
dependent translational repression of p21 and Pim-1 overexpression are key mechanisms to 
promote proliferation of K562 cells. 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results and discussion, Manuscript 1 
 
 
36 
 
Introduction 
 
The activity of kinases and mechanisms that control apoptosis and cell proliferation are often 
deregulated in cancer cells [1]. Pim-1, a serine/threonine kinase, is up-regulated in several 
cancer types and can function in a synergistic manner with the transcription factor c-Myc to 
establish severe forms of B cell lymphomas [2-4]. 
Pim kinases belong to the small group of constitutively active kinases [5]. Thus, their 
kinase activity correlates with their cellular expression levels. Expression of Pim-1 is mainly 
regulated at the transcriptional level by the action of several interleukines and growth factors 
that activate STAT3 and/or STAT5 via Janus kinases [6, 7]. For the Pim-1 kinase, several 
phosphorylation targets have been identified, such as Cdc25A [8] and Cdc25C [9], 
HP1gamma [10], Tudor-SN [11], p21 [12] and others (for review see 7]). 
The stability of Pim-1 is controlled by the heat shock proteins Hsp90 and Hsp70 as 
well as the protein phosphatase PP2A [13-15]. Hsp90 increases the half-life of Pim-1 by 
protecting it from proteasomal degradation, whereas Hsp70 has the opposite effect [15]. The 
prolyl-isomerase Pin1 is thought to mediate binding of phosphorylated Pim-1 to the 
regulatory subunit B56-beta of PP2A, leading to dephosphorylation by the catalytic subunit of 
PP2A followed by ubiquitinylation and degradation of Pim-1 via the proteasome [14]. 
Additionally, PP2A can induce apoptosis by dephosphorylation of the pro-apoptotic protein 
Bad [16], which is also a phosphorylation target of Pim-1 and Pim-2 [17, 18]. Pim-dependent 
Bad phosphorylation at serine 112 results in its cytoplasmic sequestration by binding to the 
14-3-3 protein. This interaction suppresses apoptosis because it prevents Bad from triggering 
mitochondrial cytochrome c release [19]. Based on these findings, the specific inhibition of 
PP2A by okadaic acid (OA) would be expected to induce an anti-apoptotic effect by 
stabilising Pim-1 and abrogating the dephosphorylation of Bad. However, this seems to 
contradict previous findings that have demonstrated an apoptotic response to OA treatment in 
the human myeloid leukemia cell line K562 [20, 21]. To shed light on these apparent 
discrepancies, we reinvestigated the relation between Pim-1 expression levels and induction 
of apoptosis in K562 cells. This revealed so far unnoticed time-dependent changes: a short 
term increase followed by a rapid degradation of Pim-1. By using RNAi we found Pim-1 to be 
essential for cell proliferation and cell cycle progression but without any effect on apoptosis.  
Furthermore, we found the cell cycle inhibitor p21, a phosphorylation target of Pim-
1[22], to be transiently induced after OA addition to K562 cells. Of note, the phosphorylated 
form of p21 localises to the nucleus, where it is thought to sterically interrupt the interaction 
of unphosphorylated p21 with PCNA, which then relieves the p21-mediated blockage of the 
DNA synthesis machinery [22, 23]. We show that p21 can function as an inducer of apoptosis 
because siRNA-mediated knockdown of p21 delays the OA-dependent induction of apoptosis 
in K562 cells. Finally, the observed differences in p21 expression upon OA-treatment 
prompted us to analyse the role of miRNAs on the repression of p21 translation. We found 
basal p21 mRNA levels in K562 cells to be completely repressed on the translational level by 
the miR-106b family members miR-17-5p and miR-20a encoded in the miR-17-92 cluster. 
Therefore, our findings suggest a complex and time-dependent network of Pim-1 and p21 
effects especially on cell proliferation and highlights the cooperative role of miRNAs in 
translational repression of p21. 
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Material and Methods 
 
Oligonucleotides, siRNAs and antibodies  
Locked nucleic acids (LNA) antisense oligonucleotides (AntimiRs) were purchased 
from RiboTask (Odense, Denmark). anti-miR-17-5p: 5’-CTGTAAGCACTmUT; anti-miR-
20a: 5’-CTATAAGCAmCTmUTA; all residues were LNA, except for isolated 2’-O-
methyl pyrimidines marked as mU and mC. LNA-14mers directed against let-7a (5´-
AACCTACTACCTCA-3´) and Escherichia coli RNase P RNA [24] were used as negative 
controls. Small interfering (si)RNAs (sense and antisense strands) were purchased from 
Dharmacon (Boulder, USA): Pim-1 siRNA, 5’-GAUAUGGUGUGUGGAGAUAUU and 5’-
UAUCUCCACACACCAUAUCUU. Vanilloid receptor 1 (VR1) siRNA (5’-
GCGAUCUUCUAUUCAAdTdT and 5’-GUUGAAGUAGAAGAUGCGCdTdT) was used 
as an unrelated negative control; VR1 is expressed in neuronal cells, but not in leukemia cells 
[25]; Pim-1 knockdown effects on cell proliferation and apoptosis were confirmed with a 
second Pim-1 specific siRNA (5‘-GGAACAACAUUUACAACUCdTdT and 5´-
GAGUUGUAAAUGUUGUUCCdTdT). The p21 siRNA was from Santa Cruz Biotechnology 
(sc-29427; Santa Cruz, CA, USA). Antibodies against p21 (sc-6246), Pim-1 (sc-13513), 
Hsp70 (sc-1060), beta-Actin (sc-47778), PP2A-B56-beta (sc-6117), c-Myc (sc-40), Tudor-SN 
(sc-34753), as well as the secondary antibody (sc-2005) were from Santa Cruz Biotechnology. 
The anti-HP1gamma antibody (05-690) was obtained from Upstate (Millipore, MA, USA) 
and the phospho-Bad antibody (7E11) was obtained from Cell Signaling Technology 
(Danvers, MA, USA). 
 
Cell culture and transfection  
Cell lines were cultured under standard conditions (37°C, 5% CO2 in a humidified 
atmosphere) in RPMI 1640 containing 10 % FCS (PAA, Cölbe, Germany). For knockdown 
experiments, K562 cells were electroporated in 4 mm cuvettes with a single pulse at 330 V for 
10 ms using a BioRad GenePulser XCell (Biorad, München, Germany). For 1 x 106 cells 2 µg 
Pim-1 siRNA, 0.5 µg LNA-AntimiRs or 0.7 µg p21 siRNA were used. Transfection of HeLa 
cells (8 x 104 cells) was performed in 24-well plates with Lipofectamine 2000. Briefly, 24 h 
after seeding in 500 µl RPMI 1640 with 10% FCS, 0.5 µg of vector DNA (plasmid “pGL3 
control” with a let-7a or an inverted let-7a target sequence) were co-transfected with 0, 10, 
50, or 100 nM of each LNA-AntimiR according to the manufacturer’s protocol. Complexation 
was performed in Optimem medium (Invitrogen, Karlsruhe, Germany) without serum. The 
transfection volume was 100 µl for each well. For inhibition of cellular PP2A Okadaic acid 
(OA) (Biomol, Hamburg, Germany) was added to the cells at a final concentration of 100 nM 
as recommended by the manufacturer for cell culture experiments (see also reference [14]). 
 
Cell Cycle Analysis 
K562 cells were transfected with siRNAs against Pim-1 or VR1 as a negative control 
[25]. After 24 h nocodazol was added to the cells (final concentration 100 ng / ml). Cells were 
incubated for additional 24 h with nocodazol to synchronise cells in the M-phase of the cell 
cycle. Then cells were washed with PBS and fresh medium was added to release the cells 
from the mitotic block. Cells were cultivated for additional 48 h before fixation in 70% 
ethanol. After RNase A treatment, propidium iodide was added to a final concentration of 50 
µg /ml. DNA content of the cells was analysed by FACS using an FACSCalibur (Becton-
Dickinson, Heidelberg, Germany).   
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RNA preparation and quantitative real-time (qRT)-PCR 
Total RNA was isolated with the RNeasy Mini Kit (Qiagen, Hilden, Germany). RT-
PCR was conducted using the Fermentas RevertAid H Minus First Strand cDNA Synthesis 
Kit (Fermentas, St. Leon-Roth, Germany) with 1 µg total RNA. Quantitative PCR was 
performed in duplicate in a LightCycler from Roche (Penzberg, Germany) with the Absolute 
QPCR SYBR Green Capillary Mix (Thermo Scientific, Hamburg, Germany). All procedures 
and reactions were carried out according to the protocols provided by the manufacturers. The 
mRNA levels were calculated from the crossing points by the 2-CT  method [26] to the 
obtained crossing points values. The -actin gene was used as an internal control. 
Primers were obtained from Metabion (Metabion, Martinsried, Germany) and 
designed with Universal ProbeLibrary (Roche Applied Biosciences, Mannheim, Germany). 
p21: forward 5´-TCACTGTCTTGTACCCTTGTGC-3´, reverse 5´-
GGCGTTTGGAGTGGTAGAAA-3´); β-actin: forward 5´-
CCAGAGGCGTACAGGGATAG-3´, reverse 5´-CCAACCGCGAGAAGATGA-3´; miR-17-
92 cluster: forward 5´-CAGTAAAGGTAAGGAGAGCTCAATCTG-3´, reverse 5´-
TCAGATTATTCTTTAGCTTAGTGGTTGTATG-3´. 
 
Western blotting 
Cells were resuspended in lysis buffer (125 mM Tris-HCl pH 6.8, 4 % SDS, 1.4 M 2-
mercaptoethanol, 0.05 % bromophenol blue) and heated at 95°C for 5 min. Samples were 
loaded onto 10% or 15% SDS-polyacrylamide gels and run for 1 h at 180 V. Proteins were 
transferred to an Immobilon-P PVDF membrane (Millipore, MA, USA) for 90 min at 1 mA 
per cm2 membrane using an EBU-4000 blotter (C.B.S. Scientific, CA, USA). Primary and 
secondary antibodies were diluted in TBST 1:200 (p21, Tudor-SN), 1:500 (Pim-1, B56-beta), 
1:1000 (Hsp70, c-Myc), 1:2000 (p-Bad), 1:4000 (HP1gamma), 1:10000 (β-Actin) and 
1:10000 (goat anti-mouse IgG-HRP). After a final washing step, blots were incubated with 
Amersham ECL or ECLplus Western blotting reagents according to the manufacturer’s 
protocol. For detection, Kodak BioMax Light Films, Kodak GBX developer/replenisher and 
GBX fixer/replenisher were used. 
 
Luciferase reporter assays, plasmid construction and seed mutagenesis 
To determine the effects of AntimiR-LNAs against mature miR-17-5p and miR-20a on 
the expression of the p21 protein, the 3´-untranslated region (UTR) of p21 was cloned into the 
pGL3 control luciferase reporter vector (Promega, Mannheim, Germany) via its XbaI site. The 
3`-UTR was initially amplified from K562 genomic DNA with the forward primer 5´-
TCTAGACCTCAAAGGCCCGCTCTA-3´ and reverse primer 5´-
TCTAGAGGAGGAGCTGTGAAAGACACA-3´; the amplicon was subcloned into a 
pCR2.1-TOPO vector as part of the TOPO TA Cloning kit (Invitrogen, Karlsruhe, Germany) 
before final insertion into the pGL3 vector. PCR mutagenesis of the miRNA target sites was 
done according to Brennecke et al. [27] using the following primers (sites of mutation 
underlined): 
5´-target site forward: 5´-GAAGTAAACAGATGGGACTGTGAAGGGGCCTCACC-3´,  
5´- target site reverse: 5´-GGTGAGGCCCCTTCACAGTCCCATCTGTTTACTTC-3´,  
3´-target site forward: 5´-CTCCCCAGTTCATTGGACTGTGATTAGCAGCGGAA-3´,  
3´-target site reverse: 5´-TTCCGCTGCTAATCACAGTCCAATGAACTGGGGAG-3´. 
1 µg of pGL3 derivatives were co-transfected with 0.5 µg of AntimiR-LNAs per 1 x 
106 cells. After 48 h, luciferase assays were performed using the Promega Luciferase Assay 
System. Briefly, cells were resolved in 100 µl lysis buffer, and 10 µl of lysate were mixed 
Results and discussion, Manuscript 1 
 
 
39 
 
with 25 µl substrate and immediately measured with a Safire2 microplate reader (Tecan, 
Crailsheim, Germany) in 96-well plates. 
 
Analysis of phosphorylated Bad levels 
To detect phosphorylation of Bad at serine 112, the CASETM kit from Superarray 
(Frederick, MD, USA) and poly-D-lysine coated plates (Corning Costar, NY, USA) were 
used. The amounts of phospho-Bad and total Bad were determined with two different 
antibodies in colour reactions; in both cases, absorbance was measured at 450 nm with a 
Safire2 microplate reader (Tecan, Germany), and the ratio of phospho-Bad to Bad was 
calculated. Note that the total Bad levels remained essentially unchanged in all measurements 
shown in Figures 1 F and 2 A (variation ≤ 20%). For the determination of relative cell 
number, cells were stained with Coomassie blue. Absorbance was measured at 595 nm and 
the ratio of phospho-Bad to Bad was normalised to the estimated cell number. 
 
Apoptosis and proliferation assays 
Using the “Cell Death Detection ELISA” (Roche, Germany), microtiter plates were 
pre-coated with an anti-histone antibody (clone H 11-4), incubated with lysed cells, followed 
by the addition of an anti-DNA antibody (clone MCA–33) and incubation for 90 minutes. For 
detection of mono- and oligonucleosomes an 2,2'-Azinobis-3- ethylbenzthiazolin-6-
sulfonsäure (ABTS) substrate solution was applied. Absorbance was measured with a Safire2 
microplate reader at 405 nm. 
To determine cell proliferation, 1 x 104 cells were seeded and cultivated under 
standard conditions. At the time points indicated, cells were pelleted and resuspended in 100 
µl PBS, and 10 µl of the tetrazolium salt WST-1 were added to determine the activity of 
mitochondrial dehydrogenases. Absorbance was measured after incubation at 37°C for 2 h at 
450 nm with 600 nm as reference wavelength using a Safire2 microplate reader. 
 
 
Results 
 
PP2A inhibition causes dynamic changes in Pim-1 and p21 levels 
Among 17 different human cancer cell lines we tested, K562 cells were found to have 
the highest Pim-1 protein levels (data not shown), consistent with earlier reports [28]. High 
levels of Pim-1 depend on the presence of growth factors and correlate with low levels of 
apoptosis; depriving K562 cells of growth factors increased apoptosis and caused a large 
decrease in Pim-1 protein levels (Supplementary Figure S1), which is in line with previous 
findings (for review see [7]). The levels of the anti-apoptotic Pim-1 protein were previously 
shown to increase after 1 h of treatment with the PP2A-specific inhibitor okadaic acid (OA) 
in the murine hematopoietic cell line BaF3 [14], although OA treatment was reported to 
induce apoptosis  [21]. Thus, to scrutinise the correlation between Pim-1 expression and 
apoptosis, we analysed the Pim-1 levels in K562 cells at different time points of OA 
treatment. This revealed time-dependent opposite effects on Pim-1 (Figure 1A). In the first 3 
h, Pim-1 levels increased, which was paralleled by a slight decrease in the basal apoptotic 
levels as measured by DNA fragmentation (Figures 1A and 1C). However, after 3 h of OA 
treatment Pim-1 levels declined rapidly, which was paralleled by a strong but transient 
induction of the p21 protein (Figure 1A); highest p21 levels were observed between 4 and 12 
h after OA treatment followed by subsequent down-regulation of p21 (see 24 h of OA 
treatment). Monitoring Pim-1 and p21 for longer time points (up to 4 days) revealed a 
decrease of both proteins to undetectable levels at ≥ 36 h of PP2A inhibition (Figure 1B). 
Results and discussion, Manuscript 1 
 
 
40 
 
Moreover, prolonged incubation with OA changed the morphology of K562 cells to 
megakaryocytes [29], which could be observed from time point 36 h on (data not shown). 
After 48 h beta-Actin and Hsp70 levels started to drop indicating degradation of the 
cytoskeleton and progressive cell death (Figure 1B). The incubation with OA had no effect on 
the steady-state levels of PP2A during the first 24 h, as inferred from unchanged levels of 
B56-beta, the PP2A subunit that interacts with Pim-1 (data not shown). Also, we did not 
observe any OA-dependent increase in the levels of Hsp70 (Figure 1A) which mediates Pim-1 
degradation. We thus conclude that K562 cells can activate an alternative yet unknown 
degradation pathway to eliminate Pim-1, which is independent from the known Pim-1 
regulators PP2A and Hsp70.  
A further consequence of OA treatment was the induction of apoptosis in K562 cells 
(Figure 1C). An increased apoptotic rate could be measured ~6 h after OA addition (Figure 
1C) and reached a maximum level after 48 h.  
Based on the fact that p21 protein levels largely increased ~4 h after OA addition 
(Figure 1A), we asked if p21 mRNA may be present in K562 cells which normally do not 
express the p21 protein. We were indeed able to detect substantial amounts of p21 mRNA by 
qRT-PCR (Figure 1D). These levels were up-regulated approx. 10-fold at 6 h after drug 
addition, consistent with the strong increase of p21 protein at this time point. Elevated p21 
mRNA levels persisted up to 24 h (Figure 1D), whereas p21 protein levels dropped again at 
this or later time points (Figures 1A, B). 
 
OA-dependent increase in Bad phosphorylation 
The coincidence of OA-induced apoptosis and down-regulation of Pim-1 at later time 
points (> 5 h) raised the question if Pim-1 degradation might be responsible for the increase in 
apoptosis. One target of Pim-1 is the apoptotic regulator Bad. Pim-dependent phosphorylation 
of Bad leads to its cytoplasmic retention, which establishes the anti-apoptotic state of Bad. 
Upon dephosphorylation, which can be catalysed by PP2A, Bad regains the capacity to 
interact with Bcl-xL to induce apoptosis. To examine if the down-regulation of Pim-1 may 
increase the levels of dephosphorylated Bad, we analysed the ratio of Bad phosphorylated at 
serine 112 to unphosphorylated Bad. We were unable to detect basal levels of phosphorylated 
Bad in untreated K562 cells, but phosphorylated Bad became visible after cells had been 
exposed to OA (Figures 1E, F). Quantitation of Bad phosphorylation by a phospho-Bad-
specific ELISA revealed a fast increase in phospho-Bad levels (~1.7-fold) due to PP2A 
inhibition. This correlated with the observed stabilisation of Pim-1 and the slight short-term 
anti-apoptotic effect during the first 3 h of OA treatment (Figures 1A, C). Yet at later time 
points, phospho-Bad levels further increased to approx. 3-fold compared to untreated cells 
(Figure 1F) despite the fact that Pim-1 was degraded. This indicates that the observed increase 
in apoptosis at > 5 h of OA treatment is mediated by a separate, Bad-independent pathway. 
Therefore, we examined if the pro-apoptotic factor Bim [30-32] may play a role in this 
process. Western blot analysis revealed that the extended long version of Bim, BimEL, is 
present in K562 cells. However, similar to Pim-1, BimEL disappeared 4 h after OA addition 
(Supplementary Figure S2). This excluded Bim as a candidate to trigger apoptosis in K562 
cells. 
 
Pim-1 knockdown inhibits cell proliferation 
An efficient knockdown of Pim-1 by RNAi (Supplementary Figure S3A) was 
generated to reveal effects specific to Pim-1. Silencing of Pim-1 had no effects on the 
expression levels of its phosphorylation targets HP1gamma, p21 and Tudor-SN. In addition, 
neither c-Myc nor B56-beta levels were affected (Supplementary Figure S3A). We further 
tested phosphorylation levels of the Bad protein after Pim-1 knockdown. We expected a 
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decrease in cellular phospho-Bad levels due to abrogating the Pim-1-catalysed 
phosphorylation of Bad, and, as a consequence, an increase in apoptosis. However, phospho-
Bad levels remained unchanged after Pim-1 knockdown (Figure 2A), as was the disposition of 
cells to undergo apoptosis (Figure 2B). This indicates that other cellular kinases like Akt [1] 
take over the function of Pim-1 with respect to phosphorylation of Bad and that a direct effect 
of Pim-1 on apoptosis is not evident in K562 cells.  
In contrast, proliferation assays revealed that the Pim-1 knockdown caused inhibition 
of cell proliferation (Figure 2C). This was accompanied by a weak but measurable effect on 
cell cycle, leading to decreased cell numbers in the G1 phase and increased cell numbers in 
G2/M (Supplementary Figure S3B). Treatment of cells with nocodazol followed by release of 
the cells from the mitotic block enhanced the effect of the Pim-1 knockdown on cell cycle 
(Figure 2D). Under these conditions the number of cells in G1-phase were substantially 
decreased compared to nocodazol-treated control cells. Likewise, the number of cells in 
G2/M-phase was elevated, demonstrating that Pim-1 is involved in regulating the progression 
of cells through G2/M-phase. We further observed that two days after releasing the cells from 
the nocodazol block in G2/M-phase, control cells (treated with control siRNA) but not Pim-1 
knockdown resumed proliferation. However, three days after nocodazol treatment (six days 
after siRNA transfection) the Pim-1 knockdown cells also regained their capacity to 
proliferate (data not shown), suggesting that siRNA inhibition attenuates after this period.  
   
Induction of p21 favours apoptosis 
Since K562 cells are p53-deficient [33] and Bad was excluded (see above) as the 
trigger of apoptosis in OA-treated K562 cells, we focussed our attention on p21. As 
mentioned, p21 is essentially not detectable in K562 cells (Figure 1A). However, its OA-
dependent induced expression suggested the need for a checkpoint control of the cell cycle 
under these conditions. To address the functional link between OA-dependent p21 expression 
and induction of apoptosis (Figures 1A, C), we combined RNAi against p21 with subsequent 
OA treatment. Under these conditions, p21 induction was repressed to a large extent (12 h) or 
even below (other time points) the level of detection (Figure 3A). The p21 knockdown 
prevented OA-dependent activation of apoptosis at time point 6 h, but apoptosis increased 
again at time point 12 h (Figure 3B). These findings demonstrate an essential role for p21 at 
the early onset (after 6 h) of apoptosis under conditions of PP2A inhibition. Furthermore, this 
suggests a compensation mechanism that becomes operational when p21 is down-regulated, 
thus substituting p21 in apoptosis induction.  
  
Basal p21 levels are repressed by miR-17-5p and miR-20a 
The fact that K562 cells harbour substantial basal levels of p21 mRNA, but do not 
express detectable amounts of p21 protein, suggest that p21 expression is controlled on the 
post-transcriptional level. Interestingly, the 3´-UTR of p21 mRNA harbours two target sites 
for members of the miR-106b microRNA family [34]. Two members of this family, miR-17-
5p and miR-20a, are encoded in the miR-17-92 cluster that is overexpressed in K562 cells and 
in human lung cancer cells (Figure 4A; [35, 36]).  
To address whether p21 mRNAs are under the control of miR-17-5p/-20a, we pursued 
an AntagomiR approach. However, instead of applying the commonly used 2´-O-methylated 
antisense oligonucleotides directed against the full-length mature miRNA [37], we explored 
shorter all-LNA AntimiRs (8- to 14-mers) complementary to the seed region in order to 
develop efficient and highly specific AntimiRs for further in vivo studies. A let-7a target side 
in the 3’-UTR of a luciferase reporter gene was used to determine the minimum AntimiR 
length for efficient miRNA inactivation [27]. Derepression leading to about 80% of maximum 
luciferasse expression was obtained with a 10-mer all-LNA AntimiR at 50 nM (Figure 4B), 
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and all-LNA 12- or 14-mer AntimiRs essentially fully derepressed the luciferase reporter at a 
concentration of 10 nM (Figure 4B). Based on these findings, we transfected K562 cells with 
14-mer all-LNA-AntimiRs against miR-17-5/-20a to analyse translational repression of p21 
mRNA. Indeed, these LNA-AntimiRs specifically released p21 mRNA from miRNA-
dependent translational repression as shown by the appearance of p21 protein (Figure 4C). 
We then transfected the all-LNA-AntimiRs into K562 cells followed by addition of OA to test 
if miRNAs miR-17-5p and miR-20a are responsible for the down-regulation of p21 levels 
after 24 h following its transient burst of expression (see Figure 1A). However, the presence 
of these LNA-AntimiRs did not affect the dynamic changes in p21 expression (Figure 4D), 
demonstrating that miR-17-5p/-20a neither affected the increase in p21 expression nor its 
down-regulation at the protein level at later time points of OA treatment. We further 
investigated the effects of AntimiRs against miR-17-5p/-20a on apoptosis because it was 
reported that an AntagomiR approach against these two miRNAs induces apoptosis in lung 
cancer cells [36]. Yet, no such effect was seen in K562 cells (Figure 4E) demonstrating that 
the OA-induced large increase in p21, but not basal low expression levels, can induce 
apoptosis. This suggests that the role of suppression of basal p21 protein levels in K562 cells 
is to favour rapid cell cycle progression rather than affecting apoptosis (see Discussion). 
  
Mutagenesis of miR-17-5p/-20a seeds in the 3´-UTR of p21 
To analyse the regulation of p21 by miRNAs of the miR-106b family in more detail, 
we fused the 3’-UTR of the p21 mRNA to a luciferase reporter gene. Luciferase activity was 
increased 1.7-fold when the p21 3’-UTR reporter construct was co-transfected with LNA-
AntimiRs specific for miR-17-5p and miR-20a, (Figure 5). Surprisingly, mutagenesis of the 
5’-proximal seed (seed 1) failed to cause a significant derepression of luciferase reporter 
expression. However, mutagenesis of the second seed (seed 2) resulted in luciferase 
derepression, comparable in strength to the observed AntimiR effect on the wildtype reporter 
(Figure 5), indicating selective miRNA binding to the seed 2 target region. Surprisingly, 
combining the seed 2 mutant construct with AntimiR treatment enhanced luciferase 
derepression to a level (~ 2.5-fold) comparable to that when both seeds are mutated. As 
expected, AntimiR treatment of the construct with both seeds mutated showed no further 
effect. Our findings indicate a cooperative effect of the two seeds in translational repression of 
p21 mRNA. 
 
 
Discussion 
 
Our primary interest was a better understanding of the role of Pim-1 with regard to cell 
proliferation and apoptosis. The human myeloid leukemia cell line K562 was selected as a 
model cell line since it expresses particularly high levels of Pim-1. It had already been 
established that Pim-1 is able to interact with c-Myc on the chromatin level, which mediates 
Pim-1-catalysed histone H3 phosphorylation, thus activating transcription of various genes 
and  increasing the transformation capacity of the cell [4]. It was further known that Pim-1 is 
able to phosphorylate Bad and thus counteract apoptosis [17, 19].  
We applied two strategies to analyse the function of Pim-1 in K562 cells in more 
detail: (i) siRNA-mediated knockdown to deplete cells specifically of Pim-1 and (ii) treatment 
of cells with the PP2A inhibitor OA. The latter more indirect strategy was pursued because 
there are intimate functional links between PP2A and Pim-1: PP2A is involved in Pim-1 
degradation and its inhibition is known to increase Pim-1 levels; also, PP2A can induce 
apoptosis by dephosphorylation of the pro-apoptotic protein Bad, which is a phosphorylation 
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target of Pim-1. Also, OA treatment had been shown to increase the cellular levels of Pim-1 
after 1 h  of drug addition in the murine hematopoietic cell line BaF3 [14], which is expected 
owing to reduced PP2A-mediated Pim-1 degradation. However, this observed increase in 
cellular Pim-1 levels apparently contradicted the reported observation that OA treatment 
causes mitotic arrest and apoptosis in K562 cells [21].  
 
Time-resolved effects of OA treatment 
To clarify the apparent discrepancy between the expected Pim-1 stabilisation and the 
induction of apoptosis upon PP2A inhibition by OA (see above), we analysed K562 cells at 
different time points after OA addition. This unveiled dynamic time-dependent changes of 
Pim-1 levels. Furthermore, a Bad-independent pathway is able to induce apoptosis in K562 
cells. Also, considering that phospo-Bad levels did not change after Pim-1 knockdown 
(Figure 2A), we infer that another kinase than Pim-1 is able to phosphorylate Bad and, 
combined with the missing dephosphorylation activity of PP2A after OA treatment, results in 
increased phospho-Bad levels.  
 
OA induces transient p21 expression 
Another novel finding of our study is the transient induction of p21 upon OA 
treatment, resulting from an increase in p21 mRNA levels. In contrast, the basal levels of p21 
mRNA in K562 cells under standard growth conditions were found to be translationally 
repressed by miR-17-5p and miR-20a (Figures 4C-E). These miRNAs, which belong to the 
miR-106b family, are encoded in the miR-17-92 cluster that is highly expressed in K562 cells 
(Figure 4A) and other chronic myeloid leukemia cell lines [35]. It has been reported that 
miRNAs from the miR-106b family are able to regulate the cell cycle by reducing p21 levels 
in immortalised human mammary epithelial cells (HMECs) [34]. In HMECs, constitutive p21 
protein levels were detectable, which were reduced approximately 2-fold when miR-106b was 
overexpressed or increased 1.5-fold when cells were transfected with AntimiRs against the 
miR-106b family [34]. This is in line with the commonly observed fine tuning of gene 
expression by miRNAs [38, 39]. In comparison, the situation in K562 cells fundamentally 
differs in that the two miR-106b family members entirely suppress translation of basal p21 
mRNA levels. Based on our findings, we think it likely that the blockage of translation of 
basal p21 mRNA levels by miR-17-5p/-20a contributes to a diminished checkpoint control in 
K562 cells, thus favouring proliferation.  
To understand the miRNA-dependent repression of p21 in more detail, we performed 
seed mutagenesis experiments. To our surprise, the mutagenesis of seed 1 had essentially no 
effect on the expression of a luciferase reporter, whereas mutagenesis of seed 2 caused a 1.7-
fold derepression, equal in strength to the AntimiR effect (Figure 5). Secondary structure 
predictions (Mfold) [40] of the p21 3´-UTR suggest that seed 2 is embedded in a structurally 
less rigid and A/U-richer region than seed 1 (data not shown). In line with our seed 
mutagenesis experiments, this would explain why miR-17-5p/-20a primarily target seed 2. 
Nevertheless, mutagenesis of both seeds resulted in a cooperative effect (2.5-fold 
derepression), suggesting that miRNA-mediated translational repression in the p21 3’-UTR is 
mechanistically more complex.  
P21 protein levels were only transiently elevated after OA addition in K562 cells and 
became again non-detectable at 24 h, although p21 mRNA levels remained high and apoptosis 
continued. We could exclude miR-17-5p/-20a as being responsible for the down-regulation of 
p21 protein at later time points because blocking these miRNAs by LNA-AntimiRs did not 
alter the OA-dependent p21 expression profile. Therefore, other mechanisms of translational 
repression and/or induction of p21 decay pathways must be responsible for the observed p21 
disappearance at later time points.  
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A pre-incubation of cells with siRNAs against p21 delayed the induction of OA-
dependent apoptosis (Figure 3B). This may be related to the protein’s capacity to interact with 
PCNA during S-phase to stall the replication fork to ensure repair of damaged DNA [41]. 
Furthermore, p21 stabilises cyclin B1 and therefore the Cdk1/Cyclin B1 complex, which 
should result in a delay of mitosis [42].  
Previously, ectopic p53 expression in K562 cells, which lack the tumor suppressors 
p53 and ARF, induced growth arrest, apoptosis and the transactivation of p21; simultaneous 
overexpression of c-Myc counteracted p53-induced apoptosis and down-regulated 
transcriptional activation of several p53 target genes including p21 [43, 44]. At first sight, 
these observations would be consistent with a key role for p21 in promoting apoptosis in 
K562 cells in general. Yet, in the same cell line, antisense inhibition of p21 did not reduce 
p53-mediated apoptosis [43], nor did up-regulation of p21 by p53 mutant proteins promote 
apoptosis [45]. Thus, a role for p21 in apoptosis seems to be context-dependent, and the delay 
in apoptosis induction upon silencing of p21 in K562 cells may be a specific consequence of 
PP2A inhibition. Assuming that Pim-1 phosphorylates p21 [12] also in K562 cells, the 
complete absence of Pim-1 in K562 cells after > 3 h of OA-treatment and the concomitant 
transient induction of p21 may result in a prevalence of unphosphorylated p21. This, in turn, 
may favour a more persistent block of the replication fork by interaction of p21 with PCNA, 
thus triggering the observed p21-dependent onset of apoptosis. 
 
Pim-1 is essential for cell proliferation, but not apoptosis, in K562 cells  
The reduction of endogenous Pim-1 levels by RNAi was previously shown to affect 
the proliferation capacity in the human lung carcinoma cell line H1299 and in K562 cells [22, 
46]. Our efficient knockdown of Pim-1 protein levels in K562 cells (Figure 2A), resulting in 
inhibition of cell proliferation (Figure 2D), substantiates these findings. In contrast to Zhang 
et al., [46], however, we did not observe significant reductions in c-Myc levels upon Pim-1 
knockdown (Supplementary Figure S3A). Instead, we demonstrate that a Pim-1 knockdown in 
K562 cells affects the cell cycle by decreasing the number of cells in G1 while increasing the 
number of those in G2/M-phase (Figure 2D), indicating a role of Pim-1 in promoting the 
transition from G2/M to G1.  
RNAi against Pim-1 had no effect on apoptosis, which is in line with the absence of a 
Pim-1 effect on the phosphorylation status of Bad (Figure 2A). Thus, at least in the absence of 
expression of the Pim-1 target p21, an effect of Pim-1 on apoptosis is not evident. Finally, our 
and previous findings suggest that the functional relationships of Pim-1 in the cellular context 
are expected to be complex and the list of known Pim-1 targets is likely incomplete. Thus, 
towards understanding the regulatory network of Pim-1 and the molecular basis underlying 
the cell proliferation block after Pim-1 knockdown, comparative global analyses of cells 
expressing Pim-1 at largely different levels will be required.  
 
Conclusions 
Figure 6 summarises our findings. We have shown that inhibition of PP2A in K562 
cells results in time-dependent dynamic and converse changes in the levels of Pim-1 and p21. 
OA-dependent induction of apoptosis is Bad-independent and an early onset of OA-induced 
apoptosis depends on transient expression of p21, as shown by siRNA-mediated knockdown 
of p21. K562 cells are able to entirely repress translation of basal levels of p21 mRNA by 
miRNAs miR-17-5p and miR-20a; yet, these miRNAs have no effect on the disappearance of 
p21 at later time points of OA treatment. Pim-1 has no detectable effect on apoptosis but is 
essential for proliferation of K562 cells. The complete cell proliferation block upon Pim-1 
depletion and the mild phenotype of Pim kinase knockout mice [47] emphasise the potential 
of Pim-1 as an anti-cancer drug target.   
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 Figure 1. Effects of PP2A inhibition on Pim-1, p21 and phospho-Bad levels as well as 
apoptosis. (A) K562 cells were treated for the indicated times (up to 24 h) with 100 nM OA. 
After cell lysis proteins were separated on 15% SDS-PAA gels and expression levels of Pim-
1, p21 and Hsp70 were analysed by Western blotting with beta-Actin as a loading control. 
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C24, mock-treated cells (no OA addition) after 24 h. (B) Protein levels (as in panel A) at later 
time points of OA treatment (36 to 96 h). Time point 0, cells lysed immediately after OA 
addition; C96, mock-treated cells (no OA addition) after 96 h. (C) DNA fragmentation at 
different time points after OA addition as a measure of apoptosis; cells were grown as in 
panels (A) and (B). Untreated cells (-OA) were used as controls for each time point. (D) p21 
mRNA levels analysed by qRT-PCR. Cells were treated with 100 nM OA for the indicated 
times, followed by isolation of total RNA and reverse transcription. Quantitation of p21 
mRNA was conducted with a light cycler and actin as an internal standard. OA treatment 
induced an approx. 10-fold increase in p21 mRNA levels compared to the basal level. (E) 
Western blot analysis with an antibody specific for Bad phosphorylated at serine 112. Cells 
were treated for 24 h with 100 nM OA in the presence of 10% (+) or 0.1% (-) FCS. Before 
OA addition, -FCS cells were deprived of serum for 72 h. Phosphorylation of Bad at serine 
112 could only be detected in the presence of OA. (F) Cells were treated with 100 nM OA for 
the indicated time periods. The amount of phosphorylated Bad was estimated by a 
quantitative ELISA. The ratio of serine 112-phosphorylated Bad protein to total Bad protein 
was determined and normalised to the cell number. Note that the total Bad levels remained 
essentially unchanged at different time points (variation ≤ 20%). The results shown in (C), 
(D) and (F) represent mean values from at least three independent experiments; errors bars are 
standard deviations (SD). 
 
Results and discussion, Manuscript 1 
 
 
51 
 
 
Figure 2. Effects of Pim-1 knockdown on Bad phosphorylation at serine 112, apoptosis and 
cell proliferation. (A) Fraction of serine 112-phosphorylated Bad for cells transfected with the 
Pim-1-specific siRNA, a sequence-unrelated control siRNA (VR1 siRNA) or without any 
siRNA; for further details, see legend to Fig. 1 F. (B) As in (A), but quantitation of DNA 
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fragmentation as a measure of apoptosis. (C) Knockdown of Pim-1 inhibited the proliferation 
of K562 cells. K562 cells were transfected with the Pim-1-specific siRNA or the control VR1 
siRNA and cell proliferation, inferred from the cleavage of the tetrazolium salt WST-1 to 
formazan by the overall activity of mitochondrial dehydrogenases, was measured at the 
indicated time points post-transfection. (D) Knockdown of Pim-1 in combination with 
nocodazol treatment reveals interference with  transition from G2/M to G1 phase of the cell 
cycle. K562 cells were transfected with the Pim-1-specific siRNA or the control VR1 siRNA. 
After 24 h, nocodazol was added; the drug was washed out after another 24 h; cells were 
analysed by FACS 48 h after release from the nocodazol-dependent M-phase block. Values 
were derived from three independent experiments. Representative FACS profiles of 
propidiume iodide stained cells after siRNA treatment are shown at the right. Data shown in 
(A) - (D) represent mean values  from at least three independent experiments; errors bars, SD. 
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Figure 3. p21 silencing retards the onset of apoptosis in OA-treated K562 cells. (A) Cells 
were transfected with the p21-specific or a control (VR1) siRNA; after 24 h, 100 nM OA was 
added to the cells, which were harvested after further 2, 6, 12 and 24 h of incubation; p21 and 
beta-Actin levels were analysed by Western blotting; mock-treated cells (no siRNA, no OA) 
were analysed in parallel; t0, K562 cells before siRNA transfection and OA addition. (B) 
Apoptosis was measured at the same time points as in panel (A) by the DNA fragmentation 
ELISA (see Experimental section). Shown are mean values from at least three independent 
experiments; errors bars, SD. 
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Figure  4. Translation of basal p21 mRNA levels is entirely repressed by miR-17-5p and miR-
20a. (A) Expression levels of the miR-17-92 cluster in different cell lines demonstrating 
overexpression in K562 cells. (B) Inhibition of the miRNA let-7a by short all-LNA AntimiRs, 
8, 10, 12 or 14 nt in length, directed against the seed region of let-7a; AntimiRs were co-
transfected with a luciferase reporter construct harbouring a single let-7a binding site. 
Concentrations of the LNA-AntimiRs are indicated. C, expression of a luciferase reporter 
harbouring an inverted let-7a sequence (set to 100%); the extent of derepression of reporter 
translation by the LNA-AntimiRs was normalised to this control. (C) p21 protein levels 
increase after transfection of K562 cells with 14-mer all-LNA-AntimiRs complementary to 
miRNAs miR-17-5p and miR-20a encoded in the miR-17-92 cluster. 14-mer all-LNA 
AntimiRs against let-7a and Escherichia coli RNase P RNA served as negative controls. 
Beta-Actin served as a loading control. (D) Transfection of K562 cells with LNA-AntimiRs 
against miR-17-5p and miR-20a neither affected the transient burst of p21 protein expression 
after 6 h nor the disappearance of p21 after 24 h of OA treatment. 24 h after transfection of 
cells with LNA-AntimiRs, OA was added. Control: no OA added. (E) Transfection of K562 
cells with AntimiRs against miR-17-5p and miR-20a did not result in the induction of 
apoptosis, as measured by DNA fragmentation 24 h post-transfection. AntimiR-dependent 
derepression of p21 is shown by the Western blot at the bottom of the graph. Quantitative 
comparison of OA-induced p21 expression and AntimiR-dependent p21 derepression revealed 
4-fold higher p21 levels after OA-treatment (data not shown). Data shown in panels B and E 
represent mean values derived from at least three independent experiments; errors bars, SD. 
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Figure  5. Mutagenesis of miR-17-5p/-20a seeds in the 3’-UTR of p21 mRNA. (A) Schematic 
presentation of the luciferase reporter consisting of the firefly luciferase structural gene fused 
to the p21 3’-UTR (control). (B) Luciferase expression was increased ~1.7-fold by 
transfection of cells with a mixture of LNA-AntimiRs against miR-17-5p and miR-20a. 
Mutagenesis of the 5’-proximal seed (seed 1) did not alter luciferase repression, whereas 
mutagenesis of seed 2 derepressed luciferase expression to a similar extent as transfection 
with LNA-AntimiRs. Mutagenesis of both seeds revealed a cooperative effect, as inferred 
from a 2.5-fold increase in luciferase activity. Seeds 1 and 2 were mutated from 5’-
GCACUUU to 5’-GgACUgU. The shown data represent mean values derived from at least 
three independent experiments; errors bars, SD. 
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Figure  6. Summary scheme to illustrate how the investigated cellular components affect the 
proliferative and/or apoptotic status of K562 cells. The OA-induced switch from proliferation 
to apoptosis affects the expression levels of Pim-1 and p21 in a time-dependent dynamic 
manner. Illustrated is the situation after 1 h (left) and 6 h (right) of OA treatment. In untreated 
K562 cells, the translation of basal p21 mRNA is completely blocked by miRNAs miR-17-5p 
and miR-20a. This block is overrun at late stages of OA-treatment (right panel) owing to 10-
fold higher p21 mRNA levels. The strong transcriptional and translational upregulation of p21 
following OA-caused PP2A inhibition leads to the onset of Bad-independent apoptosis. Pim-1 
expression promotes proliferation, inferred from the fact that a specific siRNA-mediated 
knockdown of Pim-1 blocks proliferation. Note that Pim-1 dependent phosphorylation of Bad 
could be compensated by other kinases. Dotted lines, indirect effects; green and red circled 
triangles: increased and decreased levels, respectively; black arrow with two red lines 
indicates blocked PP2A activity; grey symbols indicate not activated or expressed; lines 
capped with a short perpendicular line illustrate inhibition. 
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Supplementary Figure S1 
 (A) K562 cells were incubated for 72 h in the presence of 10% (+) or 0.1% (-) FCS. 
Apoptosis was quantified with a DNA fragmentation ELISA (see Materials and Methods). 
Results are based on three independent experiments. (B) K562 cells were treated for 24 h with 
100 nM OA in the presence of 10% (+) or 0.1% (-) FCS. After cell lysis proteins were 
separated on a 10% SDS-PAA gel and the expression of Pim-1 was analyzed by western 
blotting with actin as a loading control. 
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ABSTRACT 
 
Nothing is known about the function of the miRNA miR-33a. Here we present first evidence 
that the proto-oncogenic serine/threonine kinase Pim-1 is a target for regulation by miR-33a: 
Pim-1, which harbours a highly conserved binding site for miR-33a, is downregulated by a 
miR-33a mimic in the erythroleukemia cell line K562 (high Pim-1 expression levels) and in 
the colon carcinoma cell line LS174T (moderate Pim-1 levels). A screen for miRNA 
expression revealed that K562 and LS174T cells have only low endogenous miR-33a levels, 
whereas other oncogenic miRNAs, namely miR-17-5p, miR-20a and miR-214, are 
overexpressed. Seed mutagenesis of the miR-33a target sequence in a luciferase reporter fused 
to the 3´-UTR of Pim-1 demonstrated the specificity of miR-33a dependent downregulation. 
A seed-directed LNA-antimiR (14-mer) slightly increased luciferase expression, suggesting 
that basal endogenous miR-33a levels in K562 cells exert a weak regulatory effect on the 
Pim-1 3’-UTR. Transfection of K562 and LS174T cells with a miR-33a mimic decelerated 
proliferation. The miR-33a dependent cell cycle defect could be assigned to an increased 
number of cells in G1-phase after.  
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INTRODUCTION 
 
MiRNAs are important regulators of gene expression, controlling developmental processes 
like embryonic stem cell differentiation, several metabolic pathways, cell proliferation, 
apoptosis and stress responses (Bartel, 2004). Like siRNAs, miRNAs are loaded into 
Argonaute (Ago)-containing “RNA-induced silencing complexes (RISC)” called miRNPs 
(Wang et al., 2009). In general, miRNAs have partial complementarity to their target mRNAs 
leading to translational inhibition or degradation of the respective mRNA in P-bodies (Liu et 
al., 2005; Rehwinkel et al., 2005). A prerequisite for miRNA interaction with mRNA targets 
is the so-called seed region covering nucleotides 2-8 of the mature miRNA strand. This region 
forms a continuous duplex with the target followed by a short unpaired region and a second 
less stringent base-pairing interaction (Lewis et al., 2005; Grimson et al., 2007).  
A growing number of miRNAs are involved in the development of cancer or metastasis, 
e.g. miR-21, members of the miR-17-92 cluster or miR-155, and are therefore called 
oncogenic miRNAs (Esquela-Kerscher and Slack, 2006). For example, the miR-17-92 cluster 
is localized to a chromosomal region which is often amplified in B-cell lymphomas, leading 
to miRNA overexpression (Ota et al., 2004). Additionally, other oncogenes like the 
transcription factor c-Myc are involved in the transcriptional regulation of miRNAs 
(O´Donnell et al., 2005). Oncogenic miRNAs can downregulate targets that are involved in 
the regulation of apoptosis or cell cycle progression, such as the phosphatase PTEN, the 
transcription factor E2F1 or the apoptotic regulator Bim (for review see Croce , 2009).  
Other miRNAs, e.g. miR-15a, miR-16-1, let-7a and miR-145, have tumor suppressor 
activity by controlling targets that can inhibit apoptosis or promote cell cycle progression, 
such as Bcl-2, Ras, Myc or cyclins (Cimmino et al., 2006; Johnson et al., 2005; Iorio et al., 
2005). In several tumors, these miRNAs are downregulated or not expressed at all (Garzon et 
al., 2009). For example, miR-15a and miR-16-1 are encoded in the chromosomal region 
13q14.3 and loss of this region is the most common genomic aberration in chronic 
lymphocytic leukemia (CLL) (Calin et al., 2002). Likewise, these two miRNAs are also often 
downregulated or not expressed in prostata carcinomas (Bonci et al., 2008). 
The tumor suppressor function of miRNAs is mainly directed against classical oncogenes, 
including the small G-protein Ras, the transcription factor c-Myc or cell cycle-dependent 
kinases like CDK4 and CDK6 (Croce, 2009). To our knowledge, there are no further 
examples of oncogenic kinases regulated by miRNAs. However, the activities of oncogenic 
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kinases are often deregulated in cancer cells (Amarvadi and Thompson, 2005). Therapeutic 
efforts have focused on the treatment of such kinases to eliminate their anti-apoptotic 
properties (Crowell et al., 2007; Martelli et al., 2007). Pim-1, a serine/threonine kinase, is up-
regulated in several cancer types and can function in a synergistic manner with the 
transcription factor c-Myc to establish severe forms of B cell lymphomas (van Lohuizen et al., 
1989; Verbeek et al., 1991; Zippo et al., 2007). Pim kinases belong to the small group of 
constitutively active kinases (Qian et al., 2005) and their kinase activity correlates with their 
cellular expression levels. For Pim-1, several phosphorylation targets have been identified, 
such as Cdc25A (Mochizuki et al., 1999), p21 (Wang et al., 2002) and others (for review see 
Bachmann and Möröy, 2005). Expression of Pim-1 is mainly regulated at the transcriptional 
level by the action of several interleukines and growth factors that activate STAT3 and/or 
STAT5 via Janus kinases (Heinrich et al., 2003; Bachmann and Möröy, 2005). Neither a 
regulation of Pim-1 by miRNAs nor a target for miR-33a have been described so far. Our data 
demonstrate that Pim-1 is a target for miRNA-dependent regulation by miR-33a, and 
overexpression of this miRNA inhibited proliferation of the two cancer cell lines under study. 
 
MATERIALS AND METHODS 
 
Oligonucleotides and antibodies 
The miR-33a Mimic (GUGCAUUGUAGUUGCAUUGCA), control Mimic 
(UCACAACCUCCUAGAAAGAGUAGA), miR-15a Mimic 
(UAGCAGCACAUAAUGGUUUGUG) and miR-16-1 Mimic 
(UAGCAGCACGUAAAUAUUGGCG) were purchased from Thermo Scientific. Pim-1 
siRNA (5’-GAUAUGGUGUGUGGAGAUAUU and 5’-
UAUCUCCACACACCAUAUCUU) were purchased from Dharmacon (Boulder, USA). An 
all-LNA-AntimiR against miR-33a (5´-GTGCATTGTAGTTTG-3´) was purchased from 
RiboTask (Odense, Denmark). Antibodies against Pim-1 (sc-13513), beta-Actin (sc-47778) as 
well as the secondary antibodies (sc-2004, sc-2005) were from Santa Cruz Biotechnology. 
 
Cell culture and transfection 
Cell lines (K562, LS174T, PC-3, DU145, LNCaP, K562, LS180, Skov-3, H69 and H209) 
were cultivated under standard conditions (37°C, 5% CO2 in a humidified atmosphere) in 
RPMI 1640 medium containing 10 % FCS (PAA, Cölbe, Germany). For transfection of K562 
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cells with miRNA mimics or siRNA, cells were electroporated in 4 mm cuvettes with a single 
pulse at 330 V for 10 ms using a BioRad GenePulser XCell (Biorad, München, Germany). 
For 1 x 106 cells, 2 µg of the respective Mimic or Pim-1 siRNA was used. LS174T cells were 
transfected with miRNA Mimics using the INTERFERin siRNA transfection reagent (Peqlab, 
Erlangen, Germany) according to the manufacturer’s protocol. Briefly, 1 x 103, 1.5 x 105 or 
2.5 x 105 cells were seeded in 96 well, 24 well or 12 well plates, respectively, and cultivated 
under standard conditions. For complexation, 0.25 to 1 µl Interferin per pmol miRNA Mimic 
was incubated with the RNA in serum-free medium for 10 min at room temperature. 
Complexes were added to the wells (5 µl Inteferin complexed with 5 pmol miRNA for 24-
well plates, 0.625 µl Interferin complexed with 2.5 pmol miRNA for 96-well plates), followed 
by incubation at 37°C in the presence of 5% CO2 for 72 h (time point of knockdown efficacy 
determination) or for the time period indicated in Fig. 6 (proliferation and apoptosis assays).   
 
RNA preparation and looped-primer qRT-PCR; qRT-PCR 
Total RNA was isolated with the RNeasy Mini Kit (Qiagen, Hilden, Germany). RT-PCR was 
conducted using the Fermentas RevertAid H Minus First Strand cDNA Synthesis Kit 
(Fermentas, St. Leon-Roth, Germany) with 1 µg total RNA. Quantitative PCR was performed 
in duplicate in a LightCycler from Roche (Penzberg, Germany) with the Absolute QPCR 
SYBR Green Capillary Mix (Thermo Scientific, Hamburg, Germany). All procedures and 
reactions were carried out according to the protocols provided by the manufacturers. The 
mRNA levels were calculated from the crossing points by the 2-CT  method (Schmittgen, 
2001) to the obtained crossing points values. Primers were obtained from Metabion 
(Metabion, Martinsried, Germany) and designed with Universal ProbeLibrary (Roche Applied 
Biosciences, Mannheim, Germany). All primers that were used for quantitative looped-primer 
PCR are listed in the supplementary file. 
 
Western blotting 
Cells were resuspended in lysis buffer (125 mM Tris-HCl pH 6.8, 4 % SDS, 1.4 M 2-
mercaptoethanol, 0.05 % bromophenol blue) and heated at 95°C for 5 min. Samples were 
loaded onto 15% SDS-polyacrylamide gels and run for 1 h at 180 V. Proteins were transferred 
to an Immobilon-P PVDF membrane (Millipore, MA, USA) for 90 min at 1 mA per cm2 
membrane using an EBU-4000 blotter (C.B.S. Scientific, CA, USA). Primary and secondary 
antibodies were diluted in TBST (Tris-buffered saline Tween-20) 1:500 (Pim-1), 1:2000 
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(CDK6), 1 1:10000 (β-Actin) and 1:4000 (secondary antibodies). After a final washing step, 
blots were incubated with Amersham ECL or ECLplus Western blotting reagents according to 
the manufacturer’s protocol. For detection, Kodak BioMax Light Films, Kodak GBX 
developer/replenisher and GBX fixer/replenisher were used. 
 
Plasmid construction, seed mutagenesis and luciferase reporter assay 
The 3’-untranslated region (UTR) of human Pim-1 was cloned into the pGL3 control 
luciferase reporter vector (Promega, Mannheim, Germany) via its XbaI site. The 3’-UTR was 
initially amplified from K562 genomic DNA with the forward primer 5’-
GCTCTAGAGCTGTCAGATGCCCGAGGG-3´ and reverse primer 5’-
GCTCTAGAGCAATAAGATCTCTTTTATTCCCCTGT-3´. GC pairs were introduced at the 
5´end for more efficient restriction according to instructions from NEB. PCR mutagenesis of 
the miRNA-33a target site was done according to Brennecke et al. (2005) using the following 
primers (sites of mutation underlined):  
5´-AAAAAATGCACAAACAGTGCGATCAACAGAAAAGCT-3´  
5´-AGCTTTTCTGTTGATCGCACTGTTTGTGCATTTTTT-3´ 
10 µg of pGL3 derivatives were co-transfected with 2 µg of miRNA mimics per 1 x 106 K562 
cells. After 48 h, luciferase assays were performed using the Promega Luciferase Assay 
System. Briefly, cells were resolved in 100 µl lysis buffer, and 10 µl of lysate were mixed 
with 25 µl substrate and immediately measured with a Safire2 microplate reader (Tecan, 
Crailsheim, Germany) in 96-well plates. 
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Proliferation assays and cell cycle analysis 
To determine K562 metabolic activity as a measure of cell proliferation, 1 x 104 cells were 
seeded and cultivated under standard conditions. At the time points indicated, cells were 
pelleted and resuspended in 100 µl PBS, and 10 µl of the tetrazolium salt WST-1 were added 
to determine the activity of mitochondrial dehydrogenases. Absorbance was measured after 
incubation at 37°C for 2 h at 450 nm with 600 nm as reference wavelength using a Safire2 
microplate reader.  
For the assessment of LS174T cell proliferation, 1 x 103 cells / well were seeded in 96-well 
plates and transfected as described above. At the time points indicated, WST-1 was diluted 
1:10 in serum-free medium and 50 µl were added to the cells. After incubation for 1 h at 
37°C, absorbance at 450 nm was measured using a MRX microplate reader. 
For cell cycle analysis, 2,5 x 105 cells were seeded in 12-well plates and transfected as 
described above. 72 h after transfection, cell growth was synchronized by adding 100 ng/ml 
nocodazole to arrest the cell cycle in the G0-G1 phase. After incubation overnight, the 
medium was replaced with nocodazole-free medium and cells were incubated for another 24 
h. Alternatively, to monitor cells during cell cycle arrest, cells were treated with 100 ng/ml 
nocodazole 96 h after transfection (Sigma, Munich, Germany), followed by incubation 
overnight. Cells were then harvested and fixed in 70% ethanol in PBS for 1 h on ice. After 
incubation with 50 µg/ml RNase A at 37°C for 30 min, cells were stained with 50 µg/ml 
propidium iodide and subjected to flow cytometric analysis using a FACSCalibur flow 
cytometer.  
 
Assays to determine apoptosis 
Using the “Cell Death Detection ELISA” (Roche, Germany), microtiter plates were pre-
coated with an anti-histone antibody (clone H 11-4), incubated with lysed cells, followed by 
the addition of an anti-DNA antibody (clone MCA–33) and incubation for 90 minutes. For 
detection of mono- and oligonucleosomes, an 2,2'-Azinobis-3-ethylbenzthiazolin-6-
sulfonsäure (ABTS) substrate solution was applied. Absorbance was measured with a Safire2 
microplate reader at 405 nm. 
To determine the apoptosis in LS174T cells, the Caspase-Glo 3/7 Assay (Promega, 
Mannheim, Germany) was used acccording to the manufacturer’s protocol. Briefly, 1 x 103 
cell were seeded in 96-well plates and transfected as described above. After 120 h, the caspase 
Glo 3/7 substrate was diluted 1+1 in serum-free medium and 100 µl were added to the cells 
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prior to incubating for 1 h at room temperature. For the detection of caspase activity, 
luminescence was measured using a FLUOstar OPTIMA microplate reader. In parallel, total 
cell numbers were determined by the WST-1 assay as described above, and readings from 
caspase 3/7 measurements were normalized for cell densities.  
 
RESULTS 
 
Screening for Pim-1 expression levels in various tumor cell lines 
Pim-1 is up-regulated in several cancer types, acts synergistically with c-Myc in B cell 
lymphoma development, and plays a key role for proliferation of cancer cells (van Lohuizen 
et al., 1989; Verbeek et al., 1991; Zippo et al., 2007; Zhang et al., 2008; Lange-Grünweller et 
al., 2010). Since Pim-1 expression levels are particularly high in our major model cell line 
K562, we were interested in relating this to Pim-1 expression in a broad spectrum of other 
tumor cell lines. For this purpose, 23 different cell lines from six different tumor types (breast, 
colon, prostata, melanoma, leukemia and ovarian) were analysed for Pim-1 expression by 
qRT-PCR (Fig. 1 A). This analysis confirmed that K562 cells stand out in terms of Pim-1 
(mRNA) expression levels which are tenfold higher than those of the leukemia cell line BM87 
showing the second highest Pim-1 mRNA levels. Apart from K562 cells, substantial amounts 
of Pim-1 mRNA were also detected in a group of other cell lines, including BM87, LS174T, 
LOVO, LS-180 (colon cancer), DU145, PC3 (prostate cancer), A2780 (ovarian cancer) and 
A431 (breast cancer). Analysis of Pim-1 levels by Western blotting for selected cell lines 
(Fig. 1 B) revealed a good correlation with the qRT-PCR data: K562 cells also had the highest 
protein levels, followed by members of the aforementioned group of cell lines (LS-180, 
LS174T, DU145 and PC3). In contrast, Pim-1 protein levels were below the detection limit of 
our Western blot setup for cell lines with lower mRNA levels, such as Skov-3 and LNCap 
(Fig. 1 B).  
 
The 3’-UTR of Pim-1 harbours a conserved binding site for miR-33a 
The particularly high expression of Pim-1 in K562 cells posed the question if Pim-1 
expression in these cells is not only transcriptionally but also posttranscriptionally 
deregulated. We thus analysed the mRNA of Pim-1 for putative miRNA binding sites by 
TargetScan 4.1 (www.targetscan.org). Five conserved sites were identified for binding of 
miR-124/506, miR-26, miR-15a/-16-1, miR-24 and miR-33a. For miR-33a, the seed region 
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from position 2-8 nt and the anchor A (Grimson et al., 2007) were found to be completely 
conserved between human, mouse, rabbit, dog and even chicken. Moreover, an unpaired 
nucleotide stretch (positions 10-12) and a second pairing region between nt 13-17, perfectly 
matching the Grimson rules (Grimson et al., 2007), was found to be conserved in all five 
eukaryotes (Fig. 2). We excluded miR-124 as a serious candidate for regulation of Pim-1 
mRNA translation in K562 cells, because miR-124 is mainly expressed in the brain and 
involved in neurogenesis and neuronal differentiation (Cheng et al., Nat. Neuroscience, 2009; 
Makeyev et al., Mol. Cell, 2007). Likewise, we disregarded miR-26 since it is evolutionary 
poorly conserved and has a lower context score compared to miR-33a (context score 
percentile for miR-26a is 77 and for miR-33a is 98 from 100). We further considered miR-15a 
/-16-1 as candidate regulators of Pim-1 expression due to their well-characterized tumor 
suppressor activities (Cimmino et al, PNAS, 2005; Aqeilan et al., Cell Death Differ. 2009), 
although their context score percentile was lower than that for miR-33a (50 for miR-15a and 
67 for miR-16-1). This is reflected in a lower adherence to the Grimson rules and a lower 
evolutionary conservation of the putative miR-15a /-16-1 target site in the Pim-1 3’-UTR 
(Fig. 2). Suppression of the tumor suppressor p16 has been attributed to miR-24 (Lal et al., 
2008). MiR-24 was not considered further here due to a lower context score percentile (77) 
for its target site in the Pim-1 3’-UTR. In conclusion, the predicted target site for miR-33a 
appeared as the most promising candidate site for miRNA regulation. Of note, no target or 
cellular function of miR-33a has been described so far.  
 
Profiling of selected miRNAs in Pim-1 expressing tumor cell lines 
Prediction of miR-15a /-16-1 and miR-33a target sites in the Pim-1 3’-UTR prompted us to 
analyse their expression levels. For this analysis, we chose the cell lines K562 and LS174T as 
model systems for very high and moderate Pim-1 expression, respectively. MiRNA profiles 
obtained for a selected set of miRNAs (including miR-423-5p and miR-374 as references that 
show minimal variability in cell lines, as recommended by Applied Biosystems for TaqMan 
microRNA assays) were determined by the looped-primer qRT-PCR technique, as shown in 
Fig. 3. Surprisingly, the miRNA miR-16-1, to which tumor suppressor functions have been 
assigned  (Cimmino et al, PNAS, 2005; Aqeilan et al., Cell Death Differ. 2009), showed the 
highest expression levels in both cell lines; levels of the related miRNA-15a were much lower 
than those for miR-16-1, but still elevated relative to those of the reference miRNA-423. 
Within the set of analysed miRNAs, also miR-214, a miRNA involved in cell survival and in 
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antagonizing apoptosis (Cheng et al., 2005), as well as the oncogenic miRNAs miR-17-5p and 
miR-20a encoded in the miR-17-92 cluster were found to be expressed at high levels. The 
miRNAs with seeds in the Pim-1 3’-UTR (miR-24, miR-26a, miR-33a and miR-124) have 
only low expression levels in both cell lines.  
 
Pim-1 is a target of miR-33a 
Relatively low expression of miR-33a in K562 and LS174T cells suggested the possibility to 
down-regulate Pim-1 protein expression by transfection of cells with a miR-33a mimic. 
Western blotting, using an optimised unspecific mimic (Thermo Scientific) as control, 
demonstrated substantial downregulation of Pim-1 by the miR-33a mimic, but not by 
corresponding miR-15a and miR-16-1 mimics in K562 cells (Fig. 4 A). A related analysis in 
LS174T cells further revealed an approx. twofold reduction in Pim-1 mRNA levels upon 
transfection with the miR-33a mimic (Fig. 4 B). We further compared the miR-33a dependent 
downregulation of Pim-1 with the knockdown efficiency of a Pim-1 specific siRNA (Lange-
Grünweller et al., 2010). The knockdown effect caused by the miR-33a mimic was as 
persistent as for the siRNA within 96 h posttransfection of K562 cells, but weaker than for the 
siRNA (Fig. 4 C). A weaker knockdown by the miR-33a mimic is consistent with the general 
trend of miRNAs to repress expression of individual targets more mildly than siRNAs 
(Selbach et al., 2008).  
 
Specificity of miR-33a binding to the Pim-1 3’-UTR 
To independently confirm repression of Pim-1 expression by the miR-33a mimic (Fig. 4 A, 
C), we cloned the 3’-UTR of Pim-1 into a luciferase reporter vector (pGL3 control). K562 
cells were cotransfected with this construct, either alone or together with the miR-33a or 
control mimic. A significant reduction of luciferase activity of around 50% was measured for 
the miR-33a mimic compared to the controls (Fig. 5 A). We further scruitinized the 
specificity of the observed miR-33a effect on Pim-1 expression by mutation of the miR-33a 
seed binding site in the 3’-UTR of Pim-1 (from 5’-CAATGCAA to 5’-CAGTGCGA). 
Luciferase reporter assays were performed with lysates derived from K562 cells transfected 
with the wildtype or mutated Luc-Pim-1 constructs, either in combination with the control 
Mimic, the miR-33a mimic, or an LNA-antimiR complementary to miR-33a. Combining the 
wildtype Luc-Pim-1 construct with the miR-33a mimic reduced luciferase activity 3 to 4-fold 
relative to the control mimic in this set of experiments (Fig. 5 B). The antimiR had, if at all, a 
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very minor effect on reporter expression, in line with the very low miR-33a levels in K562 
cells (Fig. 3). In contrast to the reporter gene carrying the wildtype 3’-UTR of Pim-1, miR-
33a dependent luciferase repression was almost fully abrogated (Fig. 5 B) when the seed 
target region was mutagenized. The mutagenized construct also tended to give rise to slightly 
increased luciferase activity (with control mimic or antimiR) compared to the wildtype 
construct, supporting the notion that low levels of endogenous miR-33a may mildly repress 
the reporter with the native Pim-1 3’-UTR.  
 
A miR-33a mimic decelerates proliferation 
Previous studies (Zhang et al., 2008; Lange-Grünweller et al., 2010) have documented a direct 
role of Pim-1 in regulating proliferation of K562 cells. We thus hypothesised that miR-33a 
may also negatively affect cell proliferation by reducing the levels of Pim-1. In a first 
experimental setup, where we transfected K562 cells with the miR-33a mimic under normal 
growth conditions (10% FCS), no effect of miR-33a on proliferation could be observed. 
However, when we reduced the level of FCS to 2% in the medium, proliferation of K562 cells 
was affected by miR-33a. This can be explained with the observation that Pim-1 levels 
decrease in K562 cells with decreasing concentrations of growth factors (Lange-Grünweller et 
al., 2010). For LS174T cells, a deceleration of cell growth owing to the miR-33a mimic was 
already seen in the presence of 10% FCS, which is attributable to the lower expression levels 
of Pim-1 in LS174T relative to K562 cells (Fig. 1 B).  
 
Discussion 
In our study we have used the webtool TargetScan 5.1 to analyse Pim-1 mRNA for 
putative miRNA target sites. This serine/threonine kinase is an important proto-oncogene 
which is up-regulated in several cancer types (van Lohuizen et al. 1989; Dhanasekaran et al. 
2001; Bachmann and Moroy 2005) and which can function in a synergistic manner with the 
transcription factor c-Myc to establish severe forms of B cell lymphomas (van Lohuizenet al., 
1989, Verbeek et al., 1991, Zippo et al., 2007). Regulation of Pim-1 expression can be mainly 
observed at the transcriptional level, however the protein has a short half-life of less than 1 
hour in tumor cells and only minutes in normal cells (Liang et al., 1996; Shay et al., 2005). 
Regulation of Pim-1 expression at the post-transcriptional level e.g. by miRNAs has not been 
investigated so far. By using TargetScan 5.1 we picked up a highly conserved target site for 
binding of miR-33a in the 3´-UTR of Pim-1. This sequence contains an 8-mer seed region 
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which defines the interaction with the miRNA and additionally an anchor A, a position at the 
3´-end of the target sequence which is often found and conserved in functional miRNA target 
sites. Moreover, an unpaired region followed by a second pairing region, is also conserved 
from human to chicken in the miR-33a target site of the Pim-1 3´UTR. Therefore, this 
sequence has a very high context score (a value defined by TargetScan, which predicts the 
possibility of functional miRNA binding) making miR-33a a perfect miRNA to regulate Pim-
1 mRNA post-transcriptionally. To test this assumption we transfected a miR-33a Mimic into 
K562 cells, an erythroleukemia cell line which overexpresses Pim-1, and found substantial 
downregulation of Pim-1 at the protein level. This demonstrates that a well defined target 
prediction programme can be successfully used to identify new miRNA targets. Another 
predicted target of miR-33a is CDK6. Current findings indicate that not all CDKs are essential 
for cell cycle regulation (among them CDK6), but rather appear important only in distinct 
tissues and cancer identities (Malumbres and Barbacid, 2009). It has a much higher context 
score (-0.80) compared to that predicted for Pim-1 (-0.40), but the predicted pairing of miR-
33a/b to those target sites in CDK6 differs substantially (see results, and suppl. figure S1) and 
we see no regulation after miR-33 targeting (data not shown). Thus global predictions and 
high ranking targets may give hints to miR-regulation of respective genes, but a detailed 
analysis of local pairing characteristics may in some cases be more informative, i.e. global 
context is less important than local context. This means that not all rules that are applied by 
TargetScan (Grimson et al. 2007) may contribute with their currently assigned emphasis to 
miR-target interaction in vivo. Another possibility is that CDK6 is regulated by other miRs in 
K562 and Hela cells, as it has an extensive 3´-UTR (~10 kb) where at least 50 conserved 
miR-binding sites are predicted by the current version of TargetScan (v5.1). So, if several 
miRs are already bound to their target sites, this may influence binding of further miRs. For 
those with lower cellular abundance we may observe competitive and stoichiometric effects in 
terms of target site access. We can find binding sites for miR-16 and miR-214, both of which 
are expressed in high amounts in the cell lines we analysed (figure 3). They have comparable 
binding characteristics as are predicted for miR-33 (suppl. figure S1). 
In tumors miRNAs can be lost or overexpressed thus making them new candidates for 
cancer therapies. MiRNAs with tumor suppressor activity can be substituted or overexpressed 
in tumor cells by using miRNA Mimics whereas oncogenic miRNAs can be blocked with 
AntimiRs. Interestingly, most of the miRNAs with tumor suppressor activity like miR-15a / 
16-1 or let-7 have more than one genomic location. This is also the case for miR-33 as two 
Results and discussion, Manuscript 2 
 
 
72 
 
singular members are located in the genome at different positions (miR-33a at chromosome 
22 q13.2 and miR-33b at chromosome 17 p11.2). It was speculated that the presence of more 
than one genomic copy of the miRNA could be an evolutionary conserved mechanism to 
preserve function of an important miRNA if one allele is deleted or silenced (Garzon et al., 
2009). Although derived from different chromosomal loci, miR-33a and miR-33b differ only 
in one additional nucleotide (A) at the 3´ end which is present in miR-33a but abesent in 
miR-33b. We cannot exclude the possibility that in our profiling using the looped primer RT-
PCR method from Chen et al. (2005) miR-33b contributed to some extent to the measured 
fraction of miR-33a. A looped primer designed for miR-33b may better discriminate 
against mir-33a due to steric interference caused by the extra A residue at the 3'-end of 
miR-33a. 
 The observation that one miRNA can have several targets (up to 200 targets per 
miRNA) and that miRNAs have more fine-tuning than knockdown properties has brought 
them into the focus for therapeutic intervention to induce apoptosis or cell cycle arrest in 
tumor cells. A recent report from the Mendell group (Kota et al., 2009) demonstrated that the 
concept of miRNA replacement therapies could be successfully applied in a mouse model of 
hepatocellular carcinoma. Since miR-26a, a miRNA with tumor suppressor activity, is 
strongly downregulated in mouse and human liver tumors, the authors pursued an AAV-
derived delivery strategy for systemic administration of miR-26a in vivo. Overexpression of 
miR-26a in HepG2 cells induces a G1 arrest by targeting the cyclins D2 and E2. Importantly, 
AAV-dependent overexpression of miR-26a led to the induction of tumor-specific apoptosis 
and, as a consequence, to a dramatic protection from disease without any toxicity (Kota et al., 
2009).  This was the first proof-of-concept study demonstrating that miRNAs can be used as 
general anti-cancer compounds. Very recently, the Slack group demonstrated the therapeutic 
potential of let-7 (Trang et al., 2009), a miRNA family whose members map to chromosomal 
regions frequently deleted in lung cancer (Calin et al., 2004). Exogenous delivery of let-7 to 
established tumors in mouse models of non-small-cell lung cancer significantly reduced the 
tumor burden. This is a further example of miRNA replacement therapy as a promising 
approach in cancer treatment. However, the route of miRNA delivery for therapeutic 
applications in the clinic is still an important issue. Liver and lung tissues are known for 
efficient uptake of miRNAs and siRNAs delivered by different ways. Other tissues such as the 
brain could not be reached by standard application systems, illustrating the many questions 
that have to be answered before miRNAs can be used in clinical applications.  
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The observation that miRNAs have moderate effects on their targets (~ 2-fold 
inhibition) raises the question why an oncogenic kinase like Pim-1 which is strongly regulated 
at the transcriptional level and additionally by PP2A-dependent degradation via the 
proteasome (Shay et al., 2005) is a target for further fine-tuning regulation by a miRNA? One 
explanation could be the fact that Pim-1 has a redundant function in cells by phosphorylating 
similar targets as Akt kinase (Amaravadi and Thompson, 2005). Pim-1 seems to lack unique 
functions thus making this kinase dispensable in knockout mice, which show only moderate 
phenotypes when all three subtypes of Pim-kinases are deleted (Mikkers et al., 2004). Only if 
Pim-1 is overexpressed like in the p53-deficient K562 cells tumorigenesis is promoted. In the 
normal cellular context Pim-1 is weakly or not expressed. However the function of Akt in 
regulating the balance between proliferation and apoptosis is central and essential for cells 
(Amaravadi and Thompson, 2005). Therefore, a backup system for this important kinase 
might be helpful for cells to counteract deregulated Akt kinase activity (Muraski et al., 2007). 
Such a backup system has to be fine-tuned and somehow coupled to the regulation of Akt 
kinase, because it only has to replace its function in conditions of Akt failure, otherwise high 
levels of Pim-1 expression would reconstitute the phenotypic effects of Akt overexpression. 
We speculate that miRNA-dependent (down)regulation of Pim-1 supports the function of Akt 
and enables cells to adjust the balance between proliferation and apoptosis. In cells like K562, 
Pim-1 overexpression would thus be indicative of a deregulated Akt kinase backup system. 
Fine-tuning of such cellular backup systems could be a function of miRNAs which is not 
addressed so far. For those reasons, Pim-1 and the Pim-1-regulating miRs appear as 
interesting targets for interference in therapeutic settings. 
Here we have added miR-33a to the list of miRNAs with tumor suppressor activity. 
We have shown that the oncogenic kinase Pim-1 is a target of miR-33a and that 
overexpression of miR-33a by transfecting a miR-33a Mimic decelerates proliferation in 
colon cancer and leukemia cell lines. Other targets of miR-33a are waiting to be identified. In 
our study we have also analysed CDK6 as a putative target for miR-33a regulation because 
CDK6 contains two putative binding sites for miR-33a in its 3´-UTR but, in this case no miR-
33a dependent downregulation could be seen in HeLa and K562 cells. Regarding the plethora 
of putative binding sites for miRs located in the CDK6 3´-UTR, it becomes clear that we need 
information on real miR-binding to those sites. Thus, our future goal is to identify further 
targets of miR-33a by using high throughput methods such as RIP-Chip (Tan et al., 2009) to 
pinpoint those predicted targets that are bound in vivo. This should lead to more information 
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about the cellular context of miR-33a/b. Until now we have not identified a cell line or 
primary cells with high expression levels of miR-33a, a prerequisite to analyse the normal 
cellular function of this miRNA. However, the fact that Pim-1 is a target of miR-33a and its 
overexpression has anti-proliferative effects might bring this miRNA into the focus for 
therapeutic applications. Currently we are on the way to examine the effects of miR-33a in 
several mouse tumor models.  
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Supplementary File:  
hsa-miR-15a, RT-PCR looped primer:  
5´-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACcacaaac-3´ 
QT PCR forward primer: 5´-TAGCAGCACATAATGGTTTGTG-3´ 
 
hsa-miR-16-1, RT-PCR looped primer: 
5´-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACcgccaat-3´ 
QT PCR forward primer: 5´- TAGCAGCACGTAAATATTGGCG-3´ 
 
hsa-miR-17, RT-PCR looped primer: 
5´-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACctacctg-3´ 
QT-PCR forward primer: 5´-CAAAGTGCTTACAGTGCAGGTAG-3´ 
 
hsa-miR-20a, RT-PCR looped primer: 
5´-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACctacctg-3´ 
QT-PCR forward primer: 5´-TAAAGTGCTTATAGTGCAGGTAG-3´ 
 
hsa-miR-24-1, RT-PCR looped primer: 
5´-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACctgttc-3´ 
QT-PCR forward primer: 5´-TGGCTCAGTTCAGCAGGAACAG-3´ 
 
hsa-miR-33a, RT-PCR looped primer: 
5´-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACtgcaatg-3´ 
QT-PCR forward primer: 5´-GTGCATTGTAGTTGCATTGCA-3´ 
 
hsa-miR-124-1, RT-PCR looped primer: 
5´-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACggcattc-3´ 
QT-PCR forward primer: 5´-TAAGGCACGCGGTGAATGCC-3´ 
 
hsa-miR-195, RT-PCR looped primer: 
5´-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACgccaata-3´ 
QT-PCR forward primer: 5´-TAGCAGCACAGAAATATTGGC-3´ 
 
hsa-miR-214, RT-PCR looped primer: 
5´-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACactgcct-3´ 
QT-PCR forward primer: 5´-ACAGCAGGCACAGACAGGCAGT-3´ 
 
hsa-miR-374a, RT-PCR looped primer: 
5´-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACcacttat-3´ 
QT-PCR forward primer: 5´-TTATAATACAACCTGATAAGTG-3´ 
 
hsa-miR-423, RT-PCR looped primer: 
5´-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACaaagtct-3´ 
QT-PCR forward primer: 5´-TGAGGGGCAGAGAGCGAGACTTT-3´ 
 
hsa-miR-486, RT-PCR looped primer: 
5´-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACggggctc-3´ 
QT-PCR forward primer: 5´-TCCTGTACTGAGCTGCCCCGAG-3´ 
Universal reverse primer: 5´-GGACCCTGCACTGGATACGAC-3´ 
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Figure 1: The 3´UTR of Pim-1 harbours a highly conserved miR-33a binding site. 
Schematic presentation of the human Pim-1 mRNA. Five conserved target sites for miRNA 
binding are located in the 3´UTR. The target site for miR-33a is the most conserved site and is 
in a sequence context predicted to be optimal for miRNA binding (context score percentile of 
98 from 100). The seed region (nt 2-8) is fully conserved from human to chicken as well as 
the central loop region (nt 10-12) and the second pairing region demonstrating that this site is 
a perfect candidate for the predicted miR-33a binding. For comparison the predicted target 
site for miR-15a is also shown. Here the target sequence in the Pim-1 3´UTR is less conserved  
between human and chicken. Moreover, the central loop region and the second pairing region 
are less evolved thus leading to a lower context score for miRNA binding to this target region. 
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Figure 2: Expression of Pim-1 in selected cancer cell lines. 
(A) Screening of 23 different tumor cell lines for Pim-1 expression by quantitative real-time 
PCR. Highest Pim-1 values were measured in colon and leukaemia cell lines. The red boxed 
cell lines were further analysed for Pim-1 expression by western blotting. (B) Western blot 
analysis revealed expression of Pim-1 in the indicated cell lines. The erythroleukemia cell line 
K562 shows highest expression levels of Pim-1. As a loading control beta-Actin was used. 
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Figure 3: miRNA profiling in K562 and LS174T cells 
(A) Expression profiling of selected miRNAs in K562 cells using the looped-primer 
technique. The miRNA miR-33a is expressed at very low levels whereas other miRNAs 
(miR-16-1, miR-17-5p, miR-20a and miR-214) are overexpressed. QRT-PCR were 
normalized against miR-423. Values were obtained from at least three separate experiments. 
(B) Expression profiling of miRNAs in LS174T cells. A similar expression pattern of 
miRNAs like in K562 cells is found in LS174T cells. Again, miR-33a is only weakly 
expressed.  
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Figure 4: Human Pim-1 is a target for miR-33a. 
(A) Pim-1 is downregulated by a transfected miR-33a Mimic in K562 cells whereas 
transfection of a control Mimic as well as miR-15a and miR-16-1 Mimics have no effect on 
Pim-1 levels. Probes were separated on 15% SDS-PAA gels and analysed by Western blotting 
with beta-Actin as a loading control. (B) Transfection of the miR-33a Mimic in LS174T cells 
revealed substantial downregulation of Pim-1 mRNA (~50%) as measured by qRT-PCR. As a 
control an unrelated siRNA was used. (C)  Persistance of Pim-1 downregulation by miR-33a 
Mimic and a Pim-1 specific siRNA is comparable whereas siRNA-dependent downregulation 
of Pim-1 is more efficient. Again beta-Actin was used as an loading control. 
Results and discussion, Manuscript 2 
 
 
85 
 
 
 
 
Figure 5: Pim-1 regulation by miR-33a is a direct effect as shown by seed mutagenesis. 
(A)  Confirmation of the western blot data by using an luciferase reporter assay containing the 
3´UTR of Pim-1. Quantification of the miR-33a Mimic effect on reporter expression reveals a 
downregulation of about 50%. The control Mimic has no effect on  luciferase expression. (B) 
The seed region of the miR-33a binding site was mutated in the luciferase vector that contains 
the Pim-1 3´UTR. Luciferase assays were performed with wildtype and mutated Pim-1 
3´UTRs. Again the repressive effect of a miR-33a Mimic under wildtype conditions is shown. 
Derepression of luciferase is shown for the mutated construct in the presence of a miR-33a 
Mimic compared to the wildtype. A slight additional derepression with a miR-33a specific 
LNA-AntimiR is observed for wildtype as well as mutated seed region. Data shown in panels 
A and B represent mean values derived from at least three independent experiments; errors 
bars, S.E.M. 
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Figure 6: The miR-33a Mimic has an anti-prolliferative effect. 
(A) Transfection of the miR-33a Mimic in K562 cells that were cultivated in the presence of 
2% FCS shows reduced proliferation rate within three days after transfection. After three days 
untreated cells or cells transfected with a control Mimic stop their growth under the applied 
conditions. (B) The miR-33a Mimic impair growth of LS174T cells compared to untreated 
cells or cells transfected with an control siRNA. Data shown in panels A and B represent 
mean values derived from at least three independent experiments; errors bars, SD. 
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Figure S1: predicted miR-pairing in the Pim-1 and CDK6 3'-UTRs 
(A) Pairing of miR-33a and miR-33b to the predicted target site in the Pim-1 3´-UTR. (B) 
Pairing of miR-33a and miR-33b to the respective binding sites in the CDK6 3´-UTR. (C) 
Binding of miR-16 and miR-214 to their predicted target sites in the CDK6 3'-UTR. The 
TargetScan alignment shows binding of respective miRs to their target sites. It can be seen 
that for Pim-1, the base-pairing involves two stretches, whereas in CDK6 only binding to the 
seed region is possible. 
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Contributions to this manuscript by the author of this thesis: 
Construction of the luciferase reporter vector containing the Pim-1 3'-UTR was a 
collaborative effort with Dorothee Hartmann. Mutated derivatives were generated by the 
author; also, experiments for figure 2B, 3A, and  5 B including primer design; writing of 
parts of the materials and methods section; first proofreading of the manuscript and 
addition of figure S1. 
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Expression analysis of miR-17-92 cluster in K562 cells 
 
Results 
 
Promoter activity of elements 5´ to the miR-17-92 start site 
 
To evaluate the role of DNA segments 5´ to the miR-17-92 cluster start site, containing a 
predicted promoter (Neural Network Promoter Prediction v2.2 software, Berkeley 
Drosophila Genome Project), several regions from this site were cloned from human 
leukemia cell line K562 into the pGL3 vector where the SV-40 promoter was replaced 
with those segments. A luciferase gene located 3´ to the segments in this vector allowed 
easy quantification of activity by luminescence read-out.   
 
 
 
Figure 1. The miR-17-92 cluster is shown with a predicted promoter (light blue, indicated 
by an arrow) and a 2 kb region upstream of the cluster start site. 1 kb downstream of the 
cluster start site a polyadenylation site is located. Magnification of the 5´ region is shown 
below. The first part is constituted of a GC-rich region with a GC-content of more than 
80% ending at 1.4 kb in front of the cluster start site (indicated in blue). Within this region 
4 c-Myc binding sites can be found (orange boxes) as well as exons 2 and 3 of the 
MIRHG1 gene (black boxes). The following 1.4 kb are AT-rich (~ 70%) and contain the 
predicted promoter (grey box) harbouring two non-consensus TATA-boxes (red boxes). 
Lightning symbols within the TATA-boxes indicate that mutations were introduced at 
those sites to down-regulate promoter activity of the respective construct (s2). The 
sequence was changed from                      5´-
GGCATAAATACGTGTCTAAATGGACCT-3´ to 5´-GGCAGAAACACGTGT-
CGAAACGGACCT-3´. The segments cloned are indicated as arrows (denominated s1-
s10). Segment s5 is an inverted version of segment s4 to assess directionality of promoter 
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activity. Segments s1 and s2 contain a single c-Myc binding site. Induction level of each 
segment is shown on the right side for K562 and for Hela cells [ND, not determined]. 
 
For each experiment, 10 µg vector with the respective segment was transfected into K562 
cells followed by luciferase read-out after 48 h. From figure 1 it can be seen that segments 
s1 and s2 containing a single c-Myc binding site show highest level of luciferase 
induction. In Hela cells, expression of s2-containing vector was not determined. A down-
regulation by ~25% is observed for mutation of both TATA-boxes (s2) when analysed in 
K562 cells. We can see a clear reduction in activity of segments containing a c-Myc 
binding site (s1 and s2) relative to those not containing such a site (s3-s10). The overall 
difference between those two groups is about 10-fold. For segments s3–s7 we see a 
decrease in promoter activity when extending the 5' deletion, the only exception being 
segment s6, which shows ~2-fold higher activity than the longer segment s4. Segments 
without the predicted core promoter (s8-s10) show also promoter activity.  
In Hela cells, the trends in activity for segments s1-s7 are similar to those observed in 
K562, although here we see a more pronounced effect of the c-Myc binding-site. That is, 
in K562 we find a 7.8 times higher induction comparing s1 with s3, and in Hela this factor 
is 29. Segments s8-s10 show also activity in Hela cells. 
 
Dependency of promoter activity on Pim-1 expression 
For determination of the influence Pim-1 exerts on the promoter segments, co-transfection 
experiments were performed by transfection of respective promoter constructs (10 µg)  
with siRNAs against Pim-1 (2 µg). As can be derived from figure 2, there is an increase of 
promoter activity under Pim-1 knockdown conditions. This effect is most prominent for 
the 1.5 kb segment s1 containing the c-Myc binding site. Here we can see an almost 2-fold 
increase of activity under Pim-1 knockdown conditions compared to control siRNA co-
transfection of this segment. Comparing segment s3 for Pim-1 knockdown and control, we 
observe an increase of activity by 1.5-fold. The shortest segment shown in this assay is 
segment s4. Here, the difference in activity is lowest and we see only 1.3-fold induction in 
comparison with the control. We can clearly infer an upregulation of promoter activity in 
those cases. Interestingly, when comparing expression levels of the unchanged pGL3 
vector harbouring the SV40 promoter, we observe a slight decrease in activity under Pim-
1 knockdown conditions (figure 2b). The expression after knockdown is reduced by 
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approximately 30%. Fragment s6 is the only case where Pim-1 knockdown decreased the 
expression level. 
 
 
 
 
a        b 
 
 
Figure 2. (a) Relative expression levels of reporter constructs containing segments s1, s3, 
and s4 are shown for conditions of Pim-1 knockdown. The 339 bp segment s4 under 
negative control conditions (VR1 siRNA) was set to 1. The first three bars indicate the 
activity under normal conditions, whereas the last three bars are the results for Pim-1 
knockdown. An increase in promoter activity can be seen under Pim-1 knockdown 
conditions (for details see text). (b) A comparison of the standard pGL3 control vector 
(carrying the SV-40 promoter) under Pim-1 knockdown and normal conditions is shown. 
Here we see a decrease in reporter expression in the knockdown setting. 
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Figure 3. Expression of further miR-17-92 5´ segments is shown here for Pim-1 
knockdown conditions. Again, for s1 a 2-fold increase in expression is seen compared to 
normal conditions. This effect is even higher (2.5-fold) for segment s4. For segment s5 the 
increase is 1.8-fold. Fragment s6 is the only case where Pim-1 knockdown decreased the 
expression level. Shown are measured RLUs (relative light units). On the right side, a 
representative Western blot for Pim-1 knockdown is shown. 
 
 
Dependency of promoter activity on c-Myc expression 
It is known that c-Myc plays a role in expression of the locus containing the miR-17-92 
cluster (Chromosome 13, ORF 25; see discussion for details). Here the goal was to 
evaluate the importance of c-Myc for the cloned regions under consideration (s1-s10). As 
described above for the Pim-1 knockdowns, c-Myc was silenced in co-transfection 
experiments. These experiments demonstrate that c-Myc significantly influences the 
expression of the cloned segment s1 as shown in figure 4. The decrease after knockdown 
is 3.1-fold for this segment and only 1.5-fold for the 625 bp segment s3 which harbours no 
c-Myc binding site. 
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Figure 4. Effects of c-Myc on promoter activity of segments s1 and s3 are shown. The 
decrease in activity is prominent (3.1-fold) for segment s1 containing a c-Myc binding 
site, but less pronounced (1.5-fold) for segment s3 lacking the c-Myc site. In the right 
panel, a representative c-Myc Western blot is shown for respective knockdown 
experiments. 
 
 
Effects of Pim-1 knockdown on miR-17-92 expression levels 
Here we wanted to investigate the miR-17-92 expression levels after Pim-1 knockdown. 
For this purpose, K562 cells were transfected with 2 µg siRNA against Pim-1. RNA was 
prepared 8 h, 24 h, and 48 h after transfection and used for qRT-PCR assays. Those initial 
experiments were conducted using primers located in exon 4 of the MIRHG1 gene in the 
locus Chr13Orf25, the expression levels of which were shown to correlate with those of 
single miRNAs (see discussion). From the data we can infer that the cluster is up-
regulated ~2-fold 48 h after Pim-1 knockdown (figure 5). The mild decrease after 8h 
seems not to be significant if one considers the error bars and also at time point 24 h after 
transfection the expression level remained essentially unchanged compared to the control. 
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Figure 5. Expression of the miR-17-92 cluster after Pim-1 knockdown. Time points 8 h, 
24 h, and 48 h are shown. In the right panel, respective Western blots for the knockdown 
experiments are depicted. 
 
 
Chromatin immunoprecipitation against HP1γ 
Heterochromatin Protein 1γ (HP1γ) is known to be recruited to sites of histone 3 
methylation at lysine 9 (H3K9) due to interaction with its chromo-domain, and thus 
contributing to silenced states of chromatin. Nevertheless, it was also found that HP1γ 
associates with actively transcribed genomic regions [1]. Furthermore, evidence for a role 
of Hp1γ in differentiation and maintenance of cancerous phenotypes was presented by 
Takanashi et al. [2]. A connection to Pim-1 is evident as it was shown that this kinase 
phosphorylates HP1γ at its chromo shadow domain (located at the carboxy terminus) 
leading to an alteration of HP1γ ´s transcriptional repression capacity [3]. 
Here we wanted to see if such interactions might play a role in regulation of the miR-17-
92 cluster. For this reason we tested HP1γ-binding to segments of the miR-17-92 cluster 
(figure 6a) and found that under Pim-1 knockdown conditions (48 h), binding of HP1γ is 
altered especially in regions A2-A5 (figure 6b, column "+AB", left and middle panels). 
Binding in region A1 is less affected.  Figure 6b (right panel) shows the binding of Pim-1 
to the regions investigated under normal growth conditions. In regions A1, A3, and A5 
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weak binding is observed, but no binding can be seen for region A2 containing the 
predicted promoter and part of the 5´ region of the miR-17-92 cluster.  
 
a 
 
b 
 
Figure 6. CHIP analysis of regions in front of and within the miR-17-92 cluster. (a) 
Primers for fragment A1 enclose a sequence containing a c-Myc binding site (the same 
site as in segments s1 and s2). A2 includes the predicted promoter. A3 and A5 include 
regions within and at the end of the miR-17-92 cluster, respectively. (b) Pim-1 
knockdown experiments were performed as described and CHIP analysis was done 48h 
after transfection. In the left panel, effects of knockdown can be seen especially for region 
A2 (predicted promoter), but also within the cluster (A3 and A5) in terms of reduced 
HP1γ binding. At region A1 (~1.5 kb upstream of the cluster start site) little effect of Pim-
1 knockdown on HP1γ binding is observed compared to controls (middle panel). In the 
right panel, Pim-1 binding to the respective regions is shown for normal cell culturing and 
growth conditions where Pim-1 localizes to region A1 and to a lesser extent to regions A3 
and A5. It is not found in A2. [+AB: specific antibody; IgG: unspecific antibody; -AB: 
control without antibody; Input: total lysate before pre-clearing steps] 
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Discussion 
Our interest in the miR-17-92 cluster concerns the relation of its high expression levels in 
K562 cells [4], and the finding that Pim-1 kinase is also highly expressed in this model 
system [5, 6]. The anti-apoptotic kinase Pim-1 is a proto-oncogene that promotes 
tumorigenesis due to synergism with c-Myc [7-9] and may play a role in regulation of this 
cluster since expression of the cluster is c-Myc-dependent [10-13]. A possibility how   
Pim-1 may influence cluster regulation is due to its interaction with HP1γ that is 
phosphorylated at its carboxy terminus (chromo shadow domain) by Pim-1, leading to 
altered association with heterochromatic genome regions and changes in transcriptional 
activity [3] (see also model in figure 7). 
We have focused our efforts on regions 5´ the miR-17-92 start site, as little is known 
about it compared to the ORF25 promoter region (see introduction). The Berkeley 
Drosophila Genome Project offers a promoter prediction tool1
                                                 
1 Neural Network Promoter Prediction v2.2, 
 that identified a putative 
promoter immediately 5´ to the cluster start site. Furthermore, the 1.4 kb region 
immediately upstream of the cluster has an AT-content of about 70% which is another 
clue to transcriptional activity. Matsubara et al. [14] found a polyadenylation site at the 
end of the miR-17-92 cluster, giving rise to the appealing assumption that the cluster may 
be transcribed as a transcription unit independent of the ORF25 locus. Our goal was to 
evaluate the promoter activity of this 5´ region. As seen in our luciferase promoter assays 
the segments 5´ to the cluster start site show such activity. From comparison of K562 and 
Hela cells we can conclude that in Hela cells, the c-Myc binding site is more important for 
regulation of the miR-17-92 cluster than in K562 cells. Also, the lower relative activity of 
segments s3-s10 in Hela indicates that in this cell line either fewer factors bind to those 
regions or inhibitory factors are responsible for this observation. Whatever the reason for 
these differences may be, our data clearly show that the region immediately upstream of 
the cluster start site harbors regulatory elements that are used in a context-dependent 
manner, i.e. they depend on cell type. Mutation of non-consensus TATA-boxes in the 
predicted promoter reduces activity of the respective construct (s2, figure 1) and 
underlines the importance of this region, albeit not to an extent as was shown for mutation 
of the locus promoter [15].  
http://fruitfly.org 
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The role of c-Myc on activity of constructs containing a c-Myc binding site is shown in 
figure 4 for K562 cells. c-Myc silencing strongly reduces activity of this segment (s1). 
Effects seen in a construct without a c-Myc site (s3) reflect the impact of c-Myc 
knockdown on cell proliferation and global transcription. It was shown by Venturini et al. 
[16] that c-Myc knockdown reduces miR-17-92 expression in K562 cells, which could be 
confirmed in our experiments (data not shown).  
Pim-1 was shown to synergistically act with a dimer of the transcription factor c-Myc and 
its binding partner Max (Myc-associated factor X) leading to an increased transcription 
from 20% of the c-Myc bound promoters in the human genome. This is due to 
phosphorylation of histone H3 at serine 10 (H3S10) by Pim-1 [9].  Regarding our data on 
the segments we cloned and their response to Pim-1 knockdown, it appears unlikely that 
this mechanism is involved here. Because segment s1 contains a c-Myc binding site, one 
would expect a decrease in reporter activity but not an increase upon Pim-1 knockdown. 
Also, for segments s3 and s4 which are much shorter and harbor no c-Myc site, an 
increase in reporter expression is seen, thus implicating a second, rather inhibitory 
mechanism of Pim-1 on miR-17-92 expression (figure 2a, figure 3). The fact that 
expression of the luciferase reporter from the SV-40 promoter is down-regulated after 
Pim-1 knockdown (figure 2b) could be assigned to the general anti-proliferative effects of 
such a knockdown (Lange-Grünweller et al., manuscript 1). At the same time, this 
supports a specific role of Pim-1 in regulation of the miR-17-92 cluster, because the 
cloned 5´ segments show activation upon Pim-1 knockdown, either containing or not 
containing c-Myc binding sites. The mechanism of this is not clear, but it appears to be 
indirect as no binding of Pim-1 is seen in the promoter and start site region of the cluster 
under normal growth conditions (region A2, figure 6b). At the moment, no data are 
available on H3S10 phosphorylation for this region that could be assigned to a Pim-1/c-
Myc interaction. Thus we focused on HP1γ, the phosphorylation state of which can be 
altered by Pim-1 and may thus influence its binding to the internal promoter region and 
expression levels at this site. In our CHIP analysis of HP1γ binding to the cluster region, 
we see a reduced binding under Pim-1 knockdown settings. This may point to a possible 
mechanism how Pim-1 may alter chromatin state and thus transcriptional activity at those 
sites, although we were not able to reveal the direct mediator molecule of Pim-1, i.e. if 
HP1γ phosphorylation is indeed responsible for the observed behavior, as 
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phosphorylation-specific antibodies failed to discriminate the bound HP1γ forms (data not 
shown). Also, as we could show that total HP1γ levels do not change under Pim-1 
knockdown (Lange-Grünweller et al., manuscript 1). Quantitative CHIP on Chip may be a 
strategy to solve this question, if appropriate antibodies are used that can clearly 
discriminate phosphorylation states of HP1γ. 
Under cellular stress conditions, the AT-rich region may be suited to integrate different 
regulatory signals as e.g. mediated by Pim-1. The miR-17-92 cluster is also upregulated 
upon growth factor depletion (data not shown). So, possibly conditions exist for which 
several regions get more important and are controlled by to date unknown mechanisms. 
For those reasons, we plan to analyze transcription under Pim-1 knockdown settings using 
qRT-PCR for several regions distributed over the whole locus (Chr13, ORF25; see figure 
8). 
 
 
 
Figure 7. Model of miR-17-92 regulation using an internal promoter. A change in Pim-1 
expression may cause alteration in HP1γ binding to regions located immediately 5´ to the 
miR-17-92 start site. Under Pim-1 knockdown conditions lack of HP1γ phosphorylation is 
proposed to lead to reduced binding of this chromatin protein, enabling higher efficiency 
of transcription, especially at the indicated site. 
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Figure 8. miR-17-92 cluster. RNA from regions indicated with orange boxes will be 
analyzed in terms of quantitative changes after Pim-1 knockdown. So far, this has only 
been done for region 8 (see also figure 5). 
 
Conclusions 
We showed that a kinase, Pim-1, influences the expression of the miR-17-92 cluster, thus 
providing another example how the microRNA "world" of the cell is interdigitated with 
factors and pathways regulating cell proliferation and apoptosis. Chromatin states and 
chromatin regulation appear to facilitate the expression of the miR-17-92 cluster. 
Evaluation of mechanisms facilitating stable inheritance of miRNA expression profiles 
[17] will probably yield new insights for intervention. 
Really surprising is the fact that Pim-1 downregulation leads to an increased miR-17-92 
expression which was shown to promote tumorigenesis (see introduction), despite the fact 
that cells proliferate less under such conditions (Lange-Grünweller et al., manuscript 1). 
An intricate cellular network may thus maintain the cancerous phenotype by anti-
apoptosis due to miR-17-92 cluster expression and proliferation due to Pim-1 expression 
in K562 cells. The upregulation of the cluster under Pim-1 knockdown conditions can thus 
be seen as an anti-apoptotic response of the cells in case of missing proliferation signals 
provided by Pim-1. Under serum-deprived conditions, a similar cluster regulation was 
seen (data not shown). Biologically and especially in the context of a cancer cell this 
response makes sense as it offers a buffer or time delay until the cell finally commits to 
apoptosis and opens up the possibility to recover from such short-term deprivations of 
growth factors. 
The connections between players involved in this anti-apoptotic program or delay of 
apoptosis remain largely unknown, but functional complementation of Pim-1 and miR-17-
92 towards maintaining the cancer phenotype is supported by our data. 
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Project design: Arnold Grünweller, Roland K. Hartmann 
  
Experiments, results and cloning for figure 1: Dorothee Hartmann, except for segment s2. 
Cloning and primer design of s1-s4, Robert Prinz. Results for s1-s4 are in accordance with 
results generated by Robert Prinz. Primer design s5-s7: Robert Prinz. Primer design s8-
s10: Arnold Grünweller. 
 
Experiments for figure 2 and figure 5: Robert Prinz 
Experiments for figure 3 and figure 4: Dorothee Hartmann. 
 
Figure 6: Arnold Grünweller, (right panel added from another figure by Arnold 
Grünweller). Experiments by Nicole Bürger, Kerstin Lange-Grünweller. Moana Klein and  
Lisa Schemberger helped in establishing the CHIP assays. 
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Appendix 
A1 Abbreviations 
Abbreviation Meaning 
A Adenosine 
Amp Ampicillin 
APS Ammonium peroxodisulfat 
Bp Base pair(s) 
BPB Bromophenol blue 
BSA Bovine serum albumine 
C cytosine 
DNA deoxyribonucleic acid 
DNase deoxyribonuclease 
dNTP deoxynucleoside triphosphates 
DTT dithiothreitol 
EDTA Ethylenediamine tetraacedic acid 
Fig. Figure 
g gram 
G guanosine 
GNA Glycol Nucleic Acid 
h hour(s) 
HEPES N-2-Hydroxyethylpiperazin-N’-2-ethane 
sulfonic acid 
KD Knock down 
l liter 
LB Luria-Bertani 
LNA Locked Nucleic Acid 
M molar [mol/l] 
mA milliampere 
Min Minute 
miR microRNA 
miRNA microRNA 
MW Molecular weight 
nt(s) Nucleotide(s) 
NTP Ribonucleosidtriphosphate 
Orf Open reading frame 
p.a. pro analysis 
PAA Polyacrylamide 
PAGE Polyacrylamid gel elektrophoresis 
PCR Polymerase chain reaction 
pmol Picomol 
qRT-PCR Quantitative Real time PCR 
QT-PCR Quantitative PCR 
RISC RNA-induced silencing complex 
RNA ribonucleic acid 
RNAi RNA interference 
RNase ribonuclease 
rpm rounds per minute 
RT-PCR Reverse transcription PCR 
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s second 
SDS Sodium Dodecyl Sulfate 
siRNA Short interfering RNA 
T Thymine 
TBE Tris-Borat-EDTA Buffer 
TEMED N,N,N,N,-Tetramethylethylendiamin 
Tm melting temperature 
Tris Tris-hydroxymethylaminomethan 
U Uridine 
XCB Xylene cyanol blue 
 
 
A2 Chemicals 
All chemicals used are in accordance with p.a. standard. 
 
Substance provider 
2- Mercaptoethanol Roth 
Acrylamid (Rotiphorese Gel 30; 37,5:1) Roth 
Agar Agar (high gel strength) Serva 
Agarose GTQ Roth 
Ammonium acetate Fluka 
Ampicillin Roth 
Bovine serum albumin (BSA) Sigma 
Bromophenol blue (BPB) Merck 
Chloramphenicol Sigma 
Chloroform Merck 
Crystal violet Fluka 
Deoxynucleosidtriphosphates (dNTPs) Fermentas 
Dithiothreitol (DTT) Gerbu 
Ethanol p.a. 99.8 % Roth 
Ethidiumbromide Roth 
Glycerol Gerbu 
Glycin Roth 
HEPES-b Gerbu 
Isopropanol p.a. Roth 
Methanol Roth 
Milk Powder blotting grade Roth 
N,N,N‘,N‘-Tetraethylmethylenediamin (TEMED) Roth 
Na Cl2 Roth 
Na SO4 Roth 
Nucleosidtriphosphates (NTPs) Roche 
Peptone Roth 
SDS running buffer (Rotiphorese 10x SDS PAGE) Roth 
SDS ultra pure Roth 
Sodiumacetate Merck 
Tris-(hydroxymethyl)aminomethane Gerbu 
Xylenecyanol blue (XCB) Serva 
Yeast extract (standard grad, low salt) Gerbu 
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Tween 20 Roth 
 
 
A3 Lab Equipment 
Plastic consumables for cell culture, bacterial growth and general lab work (PCR tubes 
etc.)  were from Sarstedt. Cell culture plates and plates for luminescence assays were from 
Greiner Bio-One. 
 
Equipment Manufacturer 
Agarose gel chamber Biorad 
Autoclave Systec V95 
Balance Sartorius 
Centrifuge Hettich universal 320 
Centrifuge (cooling function) Heraeus Fresco 17 
Centrifuge (cooling function) Eppendorf 5810R 
Electroporator Gene Pulser Xcell 
Gel documentation system Cybertech, CS1 with Mitsubishi Video Copy 
Processor; Biostep, GelSystem MINI 
Incubater (humidified) Nuaire, DHD Autoflow 
Incubator Memmert BE400 Memmert 
Incubator, shaking GFL, Model 3033 
Lab shaker IKA, Vibrax-VXR 
Lab shaker Eppendorf Thermomixer 5436 
LightCycler 2.0 Roche 
Magnetic stirrers Heidolph 
Microscope Motic AE20 
PCR cycler Biometra TGradient Thermocycler 
Photospectrometer Thermo Biomate 3 
Platereader (multiformat) Tecan, Safire II 
Power supply Bio-Rad Power Pac 3000 
Protein Gel chamber Bio-Rad Mini Protean 3 cell 
Quartz cuvette Hellma 104-QS, 105.202, 115B-QS, 105 
Semi dry blotter C.B.S. Scientific 
Shaking incubator GFL 3033 
Sterile bench Hera Safe KS 15 
Thermoblock TB1 Biometra 
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A4 Software 
Microsoft Office 2007, Grafit 3.04,  NEBCutter 2.0, miRBase (http://www.mirbase.org/), 
Manipulate and Display a DNA Sequence (http://arbl.cvmbs.colostate.edu/molkit/manip/),  
Berkeley Drosophila Genome Project - Neural Network Promoter Prediction v2.2 (March 
1999) (http://www.fruitfly.org/seq_tools/promoter.html), EMBOSS Pairwise Alignment 
Algorithms (http://www.ebi.ac.uk/Tools/emboss/align/index.html), Integrated DNA 
Technologies Oligo Analyzer 3.1 
(http://eu.idtdna.com/analyzer/Applications/OligoAnalyzer/), TargetScanHuman 5.1 
(http://www.targetscan.org/). 
 
A5 Primer List 
Primers for cloning Pim-1 3´-UTR 
 
5´-GCTCTAGAGCTGTCAGATGCCCGAGGG-3 
Name: Inv. hPim-1 3´UTR F CCE 
5´-GCTCTAGAGCAATAAGATCTCTTTTATTCCCCTGT-3´ 
Name: Inv. hPim-1 3´UTR F CCE 
 
GC pairs are introduced for more efficient restriction. This was done according to 
instructions from NEB. 
 
Primer for mutagenesis of Pim-1 3´-UTR miR-15/16seed 
 
5´-TTGCCTCTTTTACCTGGTGGTTCTCCAAAAATCTG-3´  
Name: Pim1 mir-15a mut f1 
5´-CAGATTTTTGGAGAACCACCAGGTAAAAGAGGCAA-3´ 
Name: Pim1 mir-15a mut r1 
 
Primer for mutagenesis of Pim-1 3´-UTR  miR-33 seed 
 
5´-AAAAAATGCACAAACAGTGCGATCAACAGAAAAGCT-3´  
Name: Pim1 mir-33a mut f1 
5´-AGCTTTTCTGTTGATCGCACTGTTTGTGCATTTTTT-3´ 
Name: Pim1 mir-33a mut r1 
 
Primers for cloning p21 3´-UTR 
 
5´-GCTCTAGAGCCCTCAAAGGCCCGCTCTA-3´ 
Name: Invitrogen p21 3´UTR F (CCE) 
5´-GCTCTAGAGCGGAGGAGCTGTGAAAGACACA-3´ 
Name: Invitrogen p21 3´UTR R (CCE) 
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Primer for mutagenesis of p21 3´-UTR miR-17/20a seeds 
 
5´-GAAGTAAACAGATGGGACTGTGAAGGGGCCTCACC-3´  
Name:  mir17/20a mut F1 
5´-GGTGAGGCCCCTTCACAGTCCCATCTGTTTACTTC-3´ 
Name: mir17/20a mut R1 
 
5´-CTCCCCAGTTCATTGGACTGTGATTAGCAGCGGAA-3´   
Name: mir17/20a mut F2 
5´-TTCCGCTGCTAATCACAGTCCAATGAACTGGGGAG-3´ 
Name:  mir17/20a mut R2 
 
Primers for cloning of putative miR-17-92 promoter regions 
 
5´-ATATAGATCTTGCCGCCGGGAAACGGGTT-3´  AGATCT BglII restr. site 
5´-ATAT overhang for more efficient restriction 
Name: miR-17-92 f1 
 
5´-ATATAGATCTCTACGCGGAGAATCGCAG-3´ AGATCT BglII restr. site 
5´-ATAT overhang for more efficient restriction  
Name: miR-17-92 f2 
 
5´-ATATAGATCTCTTTAGACAATGTACCTTTTCTG-3´ AGATCT BglII restr. site 
5´-ATAT overhang for more efficient restriction  
Name: miR-17-92 f3 
 
5´-ATATAAGCTTCCATACAAATTCAGCATAATCCCTAATGG-3´  
AAGCTT HindIII restr. Site  5´-ATAT overhang for more efficient restriction 
Name: miR-17-92 r1 
 
 
Primer for mutagenesis of putative TATA boxes in miR-17-92 promoter region 
 
5´-TAAAGAATTCTTAAGGCAGAAACACGTGTCGAAACGGACCTCATA-
TCTTTG-3´ 
Name: PROMO 17-92 MUT F 
 
5´-CAAAGATATGAGGTCCGTTTCGACACGTGTTTCTGCCTTAA-
GAATTCTTTAC-3´ 
Name: PROMO 17-92 MUT R 
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Mir-17-92 LOCUS Expression-Profile Analysis: LOCUS SURFING PRIMERS 
 
5´-CTCCGGTCGTAGTAAAGCGCAGG-3´ Name: LSP 1 b F 
5´-CAGGAGGAGTAGCCGCCACC-3´ Name: LSP 1 b R 
FRAGMENT: 90 bp 
 
5´-TGCCGCCGGGAAACGGGTT-3´ Name: LSP 2F 
5´-GCAGTTTAGGAACAGAAGACC-3´ Name: LSP 2R 
FRAGMENT: 198 
 
 
5´-GTGTGGCAGCCGCATCTGGCTG-3´ Name: LSP 2 b F 
5´-CTCGGGAGAAACTTTCCTACCCAGAG-3´ Name: LSP 2 b R 
FRAGMENT: 269 bp 
 
5´-GGAAGAGCCACCACTTCCAGT-3´ Name: LSP 3 F 
5´-CCATACAAATTCAGCATAATCCCTAATGG-3´ Name: LSP 3 R 
FRAGMENT: 160 bp 
 
5´-GTTGTTAGAGTTTGAGGTGTTAATTCTAAT-3´  Name: LSP 4a F 
5´-GGTCACAATCTTCAGTTTTACAAGGTG -3´ Name: LSP 4a R 
FRAGMENT 93 bp 
 
5´-ACTGCAGTGAAGGCACTTGT -3´ Name: LSP 4b F (A3) 
5´-TGCCAGAAGGAGCACTTAGG-3´ Name: LSP 4b R (A3) 
FRAGMENT: 167bp 
 
5´-GATCGGTTGCAATGCTGTGTTTC-3´ Name: LSP 5 F  
5´-TGTATCTTGTACATTTAACAGTGGAAGTCG-3´ Name: LSP 5 R 
FRAGMENT: 140 bp 
 
5´-GCGTGTCAGATTTGGCAGTAT-3´ Name: LSP 6 F 
5´-CAGAGCGGCATTCTCTCTAAATT-3´ Name: LSP 6 R 
FRAGMENT: 242 bp 
 
5´-CCTGAGAAAAAACAACTTTGACCCTTG-3´ Name: LSP 7 F 
5´-GAAAGTTGTACATGCAAACGCC -3´ Name: LSP 7 R 
FRAGMENT: 160 bp 
 
5´-CAGTAAAGGTAAGGAGAGCTCAATCTG-3´ Name: LSP 8 F (Scherr) 
5´-TCAGATTATTCTTTAGCTTAGTGGTTGTATG -3´ Name: LSP 8 R (Scherr) 
FRAGMENT: 115 bp 
 
5´-GGGTCATTAGGAAAATGCACATATTCCATG-3´ Name: LSP 9 F 
5´-CTCAAACAGCCAGACCAAACTG-3´ Name: LSP 9 R 
FRAGMENT:  150 bp 
 
 
Appendix 
 
 
108 
 
Sequencing Primers 
 
pGL3 vector: Sequences provided by the manufacturer were used. Longer constructs 
needed sequencing from within. Sequences can be found below. 
 
Pim-1 
5´-TCTCCAAAAATCTGCCTGGGTT-3´ Primer for sequencing of the 3´-UTR 
Name: Pim-1 3rd 
 
p21 
5´-TCCTCTAAGGTTGGGCAGGG-3´ 3rd Primer for sequencing of the 3´-UTR 
Name: p21 3´UTR 3rd seq primer 
 
miR-17-92 
For long constructs, sequences from cloning of shorter fragments were used for 
sequencing reaction.  
 
 
Looped Primers for RT-PCR of mature miRNAs 
 
Primers named “QT” are forward primers for the quantitative PCR that are equal to the 
mature miRNA sequence. Primers named “loop” are primers used in RT-PCR reactions. 
 
5´-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACctacctg-3´ 
Name: mir-20a loop 01 
5´-TAAAGTGCTTATAGTGCAGGTAG-3´ 
Name: mir-20a QT 01 
 
5´-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACctacctg-3´ 
Name: mir-17 loop 01 
5´-CAAAGTGCTTACAGTGCAGGTAG-3´ 
Name: mir-17 QT 01 
 
5´-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACtgcaatg-3´ 
Name: mir-33a loop 01 
5´-GTGCATTGTAGTTGCATTGCA-3´ 
Name: mir-33a QT 01 
 
5´-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACcacaaac-3´ 
Name: mir-15a loop 01 
5´-TAGCAGCACATAATGGTTTGTG-3´ 
Name: mir-15a QT 01 
 
5´-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACcgccaat-3´ 
Name: mir-16-1 loop 01 
5´-TAGCAGCACGTAAATATTGGCG-3´ 
Name: mir-16-1 QT 01 
Appendix 
 
 
109 
 
5´-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACagcctat-3´ 
Name:  mir-26a loop 01 
5´-TTCAAGTAATCCAGGATAGGCT-3´ 
Name: mir-26a QT 01 
 
5´-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACggcattc-3´ 
Name: mir-124-1 loop 01 
5´-TAAGGCACGCGGTGAATGCC-3´ 
Name: mir-124-1 QT 01 
 
5´-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACaaagtct-3´ 
Name: mir-423 loop 01 
5´-TGAGGGGCAGAGAGCGAGACTTT-3´ 
Name: mir-423 QT 01 
 
5´-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACcacttat-3´ 
Name: mir-374a loop 01 
5´-TTATAATACAACCTGATAAGTG-3´ 
Name: mir-374a QT 01 
 
5´-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACggggctc-3´ 
Name: mir-486 loop 01 
5´-TCCTGTACTGAGCTGCCCCGAG-3´ 
Name: mir-486 QT 01 
5´-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACagtacat-3´ 
Name: mir-144 loop 01 
5´-TACAGTATAGATGATGTACT-3´ 
Name: mir-144 QT 01 
 
5´-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACatacata-3´ 
Name: mir-1-1 loop 01 
5´-TGGAATGTAAAGAAGTATGTAT-3´ 
Name: mir-1-1 QT 01 
 
5´-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACgccaata-3´ 
Name: miR-195 loop 01 
5´-TAGCAGCACAGAAATATTGGC-3´ 
Name:  miR-195 QT 01 
 
5´-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACactgcct-3´ 
Name: miR-214 loop 01 
5´-ACAGCAGGCACAGACAGGCAGT-3´  
Name:  miR-214 QT 01 
 
5´-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACttcaaaa-3´ 
Name: miR-424 loop 01 
5´-CAGCAGCAATTCATGTTTTGAA-3´ 
Name:  miR-424 QT 01                    
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5´-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACacaaacc-3´ 
Name: miR-497 loop 01 
5´-CAGCAGCACACTGTGGTTTGT-3´ 
Name:  miR-497 QT 01 
                       
5´-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACctgttc-3´ 
Name: miR-24-1 loop 01 
5´-TGGCTCAGTTCAGCAGGAACAG-3´ 
Name:  miR-24-1 QT 01 
 
5´-GGACCCTGCACTGGATACGAC-3´ Reverse primer for all QT-PCR reactions. 
Name: uni loop rev QT 01 
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A6 Map of pGL3control vector 
 
Reproduced data sheet from Promega. 
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